First Insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study 1 2

- Philipp Rausch^{1*}, Ilka Ratien^{2,3,4*}, Lukas Tittmann^{2,3}, Janna Enderle^{2,5}, Eike Matthias 3
- Wacker¹, Kathrin Jaeger^{2,3}, Malte Christoph Rühlemann¹, Katrin Franzpötter², Pierre Ellul⁶, 4
- Robert Kruse⁷, Jonas Halfvarson⁷, Dirk Roggenbuck^{8,9}, David Ellinghaus¹, Gunnar Jacobs^{2,3}, 5
- Michael Krawczak¹⁰, Stefan Schreiber^{1,11}, Corinna Bang¹, Wolfgang Lieb^{2,3*}, Andre Franke^{1*} 6
- *denotes equal contribution 7
- ¹ Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany 8 9
- ² Institute of Epidemiology, University Hospital Schleswig-Holstein, University of Kiel, Kiel, 10
- Germany 11
- ³ popgen biobank, University Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany 12
- ⁴ Department of Internal Medicine II, University Cancer Center Schleswig-Holstein, 13
- University Hospital Schleswig-Holstein, Kiel, Germany 14
- ⁵ Institute of Human Nutrition and Food Science, University of Kiel, Kiel, Germany 15
- ⁶ Division of Gastroenterology, Department of Medicine, Mater Dei Hospital, Malta 16
- ⁷ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, 17
- Örebro, Sweden 18
- ⁸ Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Germany 19 20
- ⁹ Medipan/GA Generic Assays GmbH, Ludwig-Erhard-Ring 3, 15827 Dahlewitz, Germany 21
- ¹⁰ Institute of Medical Informatics and Statistics, University Hospital Schleswig-Holstein, 22
- University of Kiel, Kiel, Germany 23
- ¹¹ Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany 24

Correspondence: Prof. Dr. Andre Franke, Christian-Albrechts-University of Kiel, University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Rosalind-Franklin-Str. 12, 24105 Kiel, Germany; a.franke@ikmb.uni-kiel.de 26 27 28

Abbreviations used: CD-Crohn's disease; IBD-inflammatory bowel disease; IC-informed consent; UC-ulcerative colitis; uIBD-undetermined inflammatory bowel disease, MD-index-Microbiome dysbiosis index; GMHI-General Microbiome Health Index; PRS-Polygenic Risk Scores **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**29 30 31 32

ABSTRACT 33

Background: The prospective Kiel Inflammatory Bowel Disease (IBD) Family Cohort Study (KINDRED cohort) was initiated in 2013 to systematically and extensively collect data and biosamples from index IBD patients and their relatives (e.g., blood, stool), a population at high risk for IBD development. Regular follow-ups were conducted to collect updated health and lifestyle information, to obtain new biosamples, and to capture the incidence of IBD during development. By combining taxonomic and imputed functional microbial data collected at successive time points with extensive anthropometric, medical, nutritional, and social information, this study aimed to characterize the factors influencing the microbiota in health and disease via detailed ecological analyses. 34 35 36 37 38 39 40 41 42

Results: Using two dysbiosis metrics (MD-index, GMHI) trained on the German KINDRED cohort, we identified strong and generalizable gradients within and across different IBD cohorts, which correspond strongly with IBD pathologies, physiological manifestations of inflammation (*e.g.,* Bristol stool score, ASCA IgA/IgG), genetic risk for IBD, and general risk of disease onset. Anthropometric and medical factors influencing transit time strongly modify bacterial communities. Various *Enterobacteriaceae* (*e.g., Klebsiella sp.*) and opportunistic *Clostridia* pathogens (*e.g., C. XIVa clostridioforme*), characterize in combination with ectopic oral taxa (*e.g. Veillonella sp.*, *Cand. Saccharibacteria sp.*, *Fusobacterium nucleatum*) the distinct and chaotic IBD-specific communities. Functionally, amino acid metabolism and flagellar assembly are beneficial, while mucolytic functions are associated with IBD. 43 44 45 46 47 48 49 50 51 52

Conclusions: Our findings demonstrate broad-scale ecological patterns which indicate drastic state transitions of communities into characteristically chaotic communities in IBD patients. These patterns appear to be universal across cohorts and influence physiological signs of inflammation, display high resilience, but show only little heritability/intrafamily transmission. 53 54 55 56 57

58

Keywords: Kiel Inflammatory Bowel Disease Family cohort, epidemiology, microbiota, 16S, dysbiosis 59 60

61

INTRODUCTION 62

Inflammatory bowel disease (IBD), with the most common manifestations of Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic, relapsing inflammation of the gastrointestinal tract [1] resulting from a complex interplay of genetic, lifestyle, and environmental factors [2–4]. The incidence and prevalence of IBD are rising in many parts of the world [5,6], and the highest incidences are currently reported in North America and Europe [6,7], while short-term projections expect a prevalence of 1% in high-income countries by the year 2030 [8]. 63 64 65 66 67 68 69

Clustering of IBD cases within families is not uncommon, suggesting a significant contribution of shared genes and lifestyle or environmental factors to IBD susceptibility [4,9– 12]. First-degree relatives of IBD patients have a 3- to 20-fold greater risk of developing the disease themselves than does the general population [4,11,13,14]. In particular, for siblings of IBD patients, estimates of the relative disease risk range from 10 to 50 [15]. Meta-analyses and genome-wide association studies (GWAS) have identified 320 loci associated with either CD or UC or both [16]. Most disease-related genes and pathways are thought to influence disease risk by altering the epithelial barrier, the gut microbiota, or the inflammatory process in general [4,17–20]. Moreover, familial aggregation of IBD has been suggested to be a risk factor for a more aggressive course of the disease, earlier disease onset, and greater need for treatment [21,22], while disease risk in families with IBD cases is generally increased [23] and can be further evaluated by polygenic risk scores derived from the accumulated genetic knowledge of the disease [24]. 70 71 72 73 74 75 76 77 78 79 80 81 82

Most prior studies on IBD risk factors used a classical case–control design, comparing IBD patients to healthy controls. However, the molecular alterations or lifestyle factors that precede or predict the pre-clinical onset of IBD can only be identified reliably in prospective studies that collect health-related information and biomaterials from unaffected or preclinical individuals over time. Given the relatively low IBD incidence in the general population and the high familial risk for IBD, a family-based prospective study represents a more efficient study design than a population-based study. However, due to the high costs of maintenance, infrastructure, participant commitment, and long run-time, this type of study design is rare but offers great potential [23]. Thus, in 2013, the Inflammatory Bowel Disease Family Cohort (KINDRED cohort), the so-called KINDRED cohort, was initiated in Kiel (Germany) to systematically collect disease-relevant data from IBD patients and their healthy relatives. The main objectives of the study were (i) to identify lifestyle factors and biomarkers that predispose patients to, or predict, the development of IBD and (ii) to characterize the longterm clinical course of IBD patients. To this end, comprehensive and high-quality biomaterial (blood, stool, hair) as well as detailed health-related, lifestyle, sociodemographic, and kinship information was collected from the participants of this study. Regular follow-ups are performed (approximately every 2 years), which are embedded into a long-term follow-up program for healthy relatives with respect to IBD onset. 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

One main driver of IBD has been identified in the microbial community inhabiting the intestinal tract. Various human population studies and animal experiments have identified a multitude of ways in which the microbiome varies and interacts with its host, eventually leading to and becoming indispensable for the development of intestinal inflammation [25]. One current hypothesis is that dysbiosis, a shift in the balance of a beneficial microbial community as a whole in favor of a proinflammatory community, eventually leads to and sustains intestinal inflammation via metabolic and immunologic alterations but not single taxa 101 102 103 104 105 106 107

[25]. These community shifts can result from disturbances introduced through environmental and lifestyle factors, diet, hygiene, medication, or even the host's genetic makeup [25–27]. However, the development of inflammation is a nonlinear and often long-lasting process that can persist preclinical (perceived healthy), although inflammation may already fester [28]. Analyzing early changes, particularly in microbial communities, and reducing the influence of treatment-related disturbances offers immense opportunities to trace the true pathological dynamics of the microbiota during the development of IBD. Thus, recent efforts in predicting IBD in healthy or preclinical individuals have successfully been employed to identify dedicated transcriptional [29], physiological [30], and microbial markers that are broadly associated with disease onset in IBD [31,32]. 108 109 110 111 112 113 114 115 116 117

118

RESULTS 119

Current status of the KINDRED cohort 120

As of April 2021, the Kiel KINDRED cohort included 1497 IBD patients and 1813 initially non-affected family members, belonging to a total of 1372 families. The data of all study participants whose baseline questionnaires were double entered and quality-checked were extracted from the database in a data freeze in March 2021, comprising 2393 individuals (1321 IBD patients and 1072 non-affected relatives). The discrepancy in the total number of study participants is due to the time lag between study inclusion and the return of biomaterial and questionnaire data (plus quality check). The baseline characteristics of the healthy participants, stratified by age, and of the IBD patients, stratified by disease subtype (CD, UC, uIBD), are summarized in Table 1 and Suppl. Tables $S3 \& S4$, respectively. 121 122 123 124 125 126 127 128 129

Available biosamples from the baseline collection were used to generate data for biomarker discovery, including genome-wide genotyping (Global Screening Array (GSA), version 2.0 130 131

(Illumina), N=1725). These data are complemented by fecal 16S rRNA-based microbiome profiles (N=1812), blood biomarker profiles (C-reactive protein, N=316; hemoglobin, N=49; mainly IBD patients), serum antibodies (ASCA IgA, N=781; ASCA IgG, N=780; anti-GP2 IgA, N=781; anti-GP2 IgG, N=781), and fecal indicators of inflammation (calprotectin, N=1763; occult hemoglobin/haptoglobin status, N=1760; Bristol stool score, N=882). For a subset from the first and second follow-ups $(N_{F1}=648, N_{F2}=539)$, 16S rRNA sequencing data, fecal calprotectin $(N_{F1}=519, N_{F2}=147)$, hemoglobin/haptoglobin measurements $(N_{F1}=516, N_{F2}=147)$ $N_{F2}=144$), Bristol stool score ($N_{F1}=316$, $N_{F2}=255$) and blood biomarkers for inflammation (Hb: NF1=203, NF2=162; CRP: NF1=179, NF2=127) were also available. Our study set included 7 cases of IBD onset (four in the BL \rightarrow F1 group, one in the F1 \rightarrow F2 group, and two in the $F2 \rightarrow F3$ group; see Figure 1A). 132 133 134 135 136 137 138 139 140 141 142

Distribution of physiological and clinical biomarkers of inflammation in the KINDRED cohort 143 144

We detected several highly interesting patterns among the biomarkers of inflammation, but our analyses focused on samples from the baseline examination because of the large number of samples and biomarkers. In the baseline samples, the concentrations of the antifungal antibodies anti-*Saccharomyces cerevisiae* antibody (ASCA) IgG and IgA decreased with age and increased with BMI (Table 2). ASCA antibody levels were greater in CD patients than in healthy controls and UC patients (Figure 1B). Furthermore, the concentration of antiglycoprotein 2 IgA and IgG (GP2), which have previously been reported to be reliable biomarkers for PSC and CD [33–35], significantly differ between healthy relatives and IBD patients, and are significantly associated with patient age, BMI and sex, with the concentration of anti-GP2 Ig's decreasing in females and increasing in males. We detected a particularly high average concentration in CD patients compared to either that in UC patients or non-IBD control subjects (Table 2). The fecal calprotectin concentration, a general measure of inflammatory processes in the gut and a metal sequestering protein, decreases with age in 145 146 147 148 149 150 151 152 153 154 155 156 157

IBD patients but significantly increases in CD patients, followed by UC patients (Figure 1B). The concentration of C-reactive protein (CRP), similar to hemoglobin (Hb) levels, both measured only in diseased individuals, increased with BMI, while Hb levels in affected males were significantly greater than for women with IBD (Figure S4). Stool consistency, as expressed by the self-reported Bristol stool score (BSS), strongly and significantly increases with age. This age-related increase in BSS was particularly strong in CD patients (Figure 1B; Table 2). This indicates that older CD patients suffer from greater bowel irritation and thus shorter intestinal passage times. At other examination time points, the associations were mostly comparable to the associations in the baseline analyses, as reported in Table 2. 158 159 160 161 162 163 164 165 166

Genetic predisposition to IBD can be expressed by polygenic risk scores (PRS) and is associated to physiological signs of inflammation 167 168

Due to the increasing number of variants associated to IBD it has become possible to quantify an individual's genetic risk or genetic predisposition to CD, UC, or IBD using Polygenic Risk Scores (PRS) [36]. On average CD- and UC-PRS were relatively disease specific as they only showed significant differences from healthy KINDRED participants in the respective patient subset, with the exception of the more general IBD-PRS which was clearly increased in CD and UC patients alike, compared to healthy control individuals (Figure 1C). Interestingly, the average UC-PRS and general IBD-PRS were significantly elevated among future onset cases, while the CD-PRS showed no clear pattern. In addition to the average higher genetic risk present in future onset cases, the probability of IBD onset was significantly associated with UC-PRS and IBD-PRS, even though only nominally statistically significant (see Table S6, Figure S6A). The genetic risk for IBD should naturally be increased in IBD patients, compared to healthy individuals in general, a pattern displayed by all three PRS variants. However, closely related healthy first-degree relatives (FDRs) showed no significantly elevated PRS. The average genetic risk for IBD did not significantly differ among healthy 169 170 171 172 173 174 175 176 177 178 179 180 181 182

FDRs, more distant relatives (>1st degree relatives), and unrelated controls (Figure S7). This pattern points to a significantly stronger accumulation of risk variants in affected individuals and onset patients, even in comparison to closely related family members and a high disease specificity of the respective PRS except for the more general IBD-PRS. 183 184 185 186

In our analyses, we tested PRS-CD, PRS-UC, and PRS-IBD for associations with different biomarkers. We detected a significant positive relationship only between CD- and IBD-PRS and the levels of ASCA-IgA/IgG and, to some extent, between IBD-PRS and the levels of anti-GP2-IgA (Figure 1D, Figure S5, Table S5). However, other inflammatory markers, such as calprotectin, BSS, CRP, and Hb did not show any, or only weak associations with genetic risk scores for IBD (Figure 1D, Figure S5, Table S5). 187 188 189 190 191 192

Differential abundance of microbial taxa across IBD pathologies and time 193

Among the three time points we investigated, the fecal communities were dominated mainly by members of the phylum Bacteroidetes, followed by members of Firmicutes and Proteobacteria, and minor taxonomic groups (*e.g.* Fusobacteria, Tenericutes, Candidatus Saccharibacteria; Figure 2A, Figure S8). At this high taxonomic level strong differences between the main IBD pathologies are detectable, as reflected in the association of Bacteriodetes and Firmicutes with the control individuals and the associations of Proteobacteria, Fusobacteria and Cand. Saccharibacteria with IBD, particularly CD (Figure S6, Table S7). These associations are consistent over time and carry down to the ASV level (see below). 194 195 196 197 198 199 200 201 202

By investigating abundance differences at the ASV level, we detected more than 750 significant differentially abundant taxa/ASVs among the main IBD pathologies (BL: 294, F1: 150, F2: 193, combined: 536; Figure 2B). At the baseline time point we detected taxa belonging to the *Enterobacteriaceae* (Gammaproteobacteria), such as *Haemophilus,* 203 204 205 206

Escherichia/Shigella, Raoultella, and *Klebsiella,* which were strongly overabundant in IBD patients (Figure 2C). Particularly in the fecal community of CD patients we observed a high abundance of *Klebsiella* and other *Enterobacteriaceae,* which persisted over time (see Figure 2C, S9, S10). In the phylum Firmicutes we found various associations with different IBD pathologies. Members of *Veillonella, Megasphaera, Dialister, Enterococcus,* and *Granulicatella* were more abundant in CD and UC patients alike. In contrast, members of the *Ruminococcaceae* (e.g. *Clostridium IV, Oscillibacter, Faecalibacterium*) are consistently overrepresented in healthy individuals. *Erysipelotrichaceae* is more abundant in IBD patients and is frequently associated with UC. Members of the *Bacteroidetes*, with the exception of some *Bacteroides sp.* are consistently more abundant in healthy individuals, *e.g. Alistipes, Prevotella, Alloprevotella, Parabacteroides*, and *Bacteroides* (see Figure 2C, S9, S10). 207 208 209 210 211 212 213 214 215 216 217

Interestingly IBD-associated taxa belonging to *Veillonella, Dialister* and *Granulicatella* (Firmicutes), but also *Haemophilus, Klebsiella* (Proteobacteria), and *Rothia* (Actinobacteria) are prominent indicators of oral colonization of the intestinal microbiome. Similarly, a rarely described disease associated taxon, *Cand. Saccharibacteria* [37] are commonly found in the oral microbiome. *Fusobacteria* (*i.e. F. nucleatum*), which are generally associated with the development of colorectal cancers, were found to be overabundant in CD patients and could also be replicated in external cohorts (see Table S8-S11). The majority of associations, such as the associations of *Veillonella*, or members of *Clostridium XIVa clostridioforme*), *Clostridium XVIII ramosum*), and *Clostridium sensu stricto* groups with IBD, or the higher abundances of ASVs belonging to *Alistipes* and *uncl. Clostridiales* in healthy individuals, can be consistently detected in external cohorts, although some incongruities exist between cohorts (*e.g. Oscillibacter* ASVs in KINDRED-Contr./SIC-IBD patients). 218 219 220 221 222 223 224 225 226 227 228 229

Various taxa showed significant correlations with clinical indicators of intestinal inflammation and genetic risk scores. Indicators of oralization correlate with physiological 230 231

signs of inflammation (e.g. *R. mucilaginosa-*BSS ↓, *Cand. Saccharibacter-*calprotectin ↑, *Klebsiella uncl.-* BSS ↑, *F. nucleatum*-calprotectin ↑, *Dialister invisus-*BSS↓ & anti-GP2 IgA/IgG ↓, *Veillonella uncl.-*IBD-PRS ↑). Interestingly, most Firmicutes correlated very consistently and almost entirely positively with the Bristol stool score (BSS) under IBD conditions (IBD, CD, UC), while members of the Bacteroidetes correlated very consistently negatively with BSS, encompassing pathobionts and commonly probiotic taxa (see Figure 2C, Table S12). This pattern was also present in healthy individuals, but did not reach significance. When we focused on the association of bacteria with genetic risk for IBD, we found that most Bacteroidetes (e.g. *Alistipes*) were correlated with decreasing genetic risk for CD, UC, and IBD, with the exception of *Bacteroides fragillis* (Figure S11, Table S13). Interestingly, *Barnesiella uncl.,* a common butyrate producer, correlated positively with genetic CD risk in healthy individuals, but correlated negatively with genetic CD risk in diseased individuals. In general, correlations with clinical parameters and genetic risk were most frequent in IBD patients, especially in CD patients, while almost no significant correlations were detected in UC patients. Different IBD associated Proteobacteria, specifically members of *Enterobacteriaceae* are strongly associated with increased ASCA IgG/IgA levels and calprotectin levels, as well as decreased gut transit time (increased BSS; *e.g. ASV_99 Escherichia/Shigella coli*) only in IBD/CD patients, similar to the findings for the IBD/CD associated Firmicutes *Clostridium XlVa clostridioforme* (ASV-103). Moreover, the *Enterobacteriaceae (e.g.* ASV-42-*Enterobacteriaceae uncl.,* ASV-165*-Citrobacter uncl.)*, as well as members of the *Clostridium XlVa* strongly correlated with increasing genetic risk for IBD, and more precisely CD in the patient cohorts (Figure 2C & Figure S11; Table S12). Several Firmicutes SCFA producers correlate with decreasing ASCA IgG/IgA levels and IBD risk in healthy and diseased individuals (e.g. ASV_71 *Faecalibacterium uncl.*), while the abundances of others correlate with elevated levels of genetic risk, particularly in diseased individuals (*e.g. Blautia, Ruminococcacea uncl.*). Overall, we observed consistent 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257

associations of ASVs to genetic risk for IBD and different clinical markers for IBD, with only minor associations in UC patients or with genetic risk for UC. 258 259

Alpha diversity patterns associated with IBD pathology, clinical characteristics, and microbial dysbiosis 260 261

A critical characteristic of ecosystems is their complexity, which can be informative for assessing the community state, productivity or stability and can be based on, e.g. the number of community members, their distribution, or their phylogenetic relationships. Overall, we identified an extensive loss of species diversity in IBD patients with respect to species richness (Figure 2D), complexity or phylogenetic relatedness of community members (NTI<0, NRI<0) (Figure S12, Table 3). Individuals suffering from CD show a significantly greater loss of diversity than UC patients based on richness and complexity but not at the phylogenetic level. Onset cases only showed a slight but insignificant reduction in diversity (less richness, less complexity, less phylogenetic dispersion). 262 263 264 265 266 267 268 269 270

Based on the differential abundance patterns we derived two indices of host health based on the bacterial abundance and distribution, namely, the Microbial Dysbiosis index (MD-index) as introduced by Gevers *et al.* (2014) and the more generalized GMHI (general microbiome health index) as developed by Gupta *et al*. (2020) [38,39]. Focusing on the MD-index we can observe a clearly negative correlation of alpha diversity with community dysbiosis at any level, further implying an accelerated loss of taxon diversity with increasing dysbiosis (breakpoint at MD=0.615, Figure 2D, Table S13). The phylogenetic composition changes to become more random with increasing dysbiosis but shows a less severe pattern than species richness or abundance distribution (Figure S12, Table S13). Across all time points we can identified a trend of strongly decreasing diversity in UC and CD patients with increasing dysbiosis, while healthy controls showed a far slower decline of diversity under increasing dysbiosis, particularly in the taxon-based indices (Table S14). The correlations of different 271 272 273 274 275 276 277 278 279 280 281 282

alpha diversity metrics with the GMHI showed comparable but weaker relationships as observed with the MD-index. Alpha diversity metrics are further negatively (Chao1, Shannon H) and positively (NRI, NTI) correlated with physiological signs of inflammation, such as ASCA-IgA/IgG, calprotectin, and BSS, particularly in IBD patients, which translates to more severe signs of inflammation at a lower community diversity in diseased individuals (CD, UC, uIBD; Figure 2G, Table S15). 283 284 285 286 287 288

Community differences between IBD pathologies are associated with clinical-, anthropometric- characteristics, patterns of community dysbiosis, and genetic risk 289 290

By investigating community similarities at different levels, we revealed various patterns of health-associated, anthropometric, and lifestyle related community differences. In particular, IBD pathology showed a strong association with community differences, with the strongest separation between microbial communities originating from healthy individuals and those originating from CD patients (Figure 3A; Table S16). In this context, we observed a strong association of the taxonomic community composition with the MD-index and to a lesser extent with GMHI (Table S16). This gradient of dysbiosis parallels the community differentiation between healthy and diseased individuals, but also recapitulates significant gradients of physiological markers for inflammation such as BSS, ASCA IgA/IgG levels, and calprotectin levels in the communities (see Figure 3A, 3B, 3J; Figure S13, S14; Table S17 & Table S18). We also detected significant, yet weak correlations between taxonomic community composition and polygenic risk scores, which were very weak for UC associated genetic risk and strongest for CD and general IBD risk at the taxonomic- (Figure S7D) and functional levels (Figure S7E) and followed the direction of the dysbiosis gradient. Similarly, the cumulative genetic risk for CD and general IBD positively correlated with the MD-index, while UC-PRS displayed no significant correlation, similar to GMHI (Figure S5B & S5C). 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306

Furthermore, onset cases were mostly distributed around the mean of the community compositional distribution and dysbiosis gradient, and thus did not represent community outliers (Figure 3C, Figure S13 & S14). The MD-index (and GMHI) strongly distinguished IBD and non-IBD individuals and corresponded with the clustering of microbial communities with respect to IBD pathology, even if applied to external patient cohorts (Sweden, Malta) (Figure 3E-3H, Figure S14G). The MD-index is most strongly elevated in CD patients and further distinguished CD patients (particularly treatment-naïve) from healthy controls in the Maltese cohort (Figure 3H). GMHI displayed on average a more consistent decrease in diseased individuals across all cohorts, and further distinguished UC patients from healthy controls (Figure S14H). These "universal" disease patterns are also reflected in the sample clustering by IBD condition, irrespective of cohort origin (conditional dbRDA (conditioned by geographic origin): $F_{4,3308}$ =4.0406, $P<0.0001$, *adj.* R^2 =0.0037) and through the significantly elevated taxonomic and functional community variability in IBD patients compared to healthy controls within (Figure 3D, Figure S14H $&$ S15, Table S20) and across cohorts (Figure 3G $&$ S14H). 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321

Both dysbiosis scores corresponded closely with several physiological signs of inflammation, such as the reactivity to fungal antigens as expressed via ASCA IgG or IgA titers, or related immunological markers, like anti-GP2 IgG and IgA levels (Figure 3I & 3J, Figure S16, Table S18). ASCA antibody levels increased most strongly in CD patients with increasing MD score (decreasing GMHI). In contrast, anti-GP2 IgA/IgG levels positively correlate with MD but appear to show a slight overall increase and higher average MD levels in CD and UC patients, as expected. Overall, the relationship of GMHI and MD-index with ASCA or anti-GP2 antibody levels were comparable (Table S18). The GMHI and MD-index displayed strong associations with the BSS, with lower stool consistency in IBD patients and increasing dysbiosis (MD ↑, GMHI ↓) (Figure 3I). The MD-index was strongly associated with 322 323 324 325 326 327 328 329 330 331

increasing BMI and calprotectin levels, which were on average higher in CD and UC patients than in healthy controls (Figure 3I, Figure 1B). The concentrations of serum CRP- and Hb levels, which were only assessed in diseased individuals, were not significantly associated with microbial dysbiosis metrics (Figure S16). The practitioner's overall assessment of disease severity in IBD patients only (1-no/4-severe inflammation), revealed a strong positive association with MD, while GMHI was not significantly correlated. 332 333 334 335 336 337

When we investigated dysbiosis patterns among FDRs, we observed that the MD and GMHI in affected individuals were greater or lower, respectively, than those in healthy family members. However, healthy FDRs of IBD patients, generally related, or unrelated healthy individuals, did not show a greater degree of dysbiosis. However, the MD-index was weakly associated with an increased probability of IBD onset (DF=1,1735, *Z*=-2.0685, *P(Z)*=0.0386, Nonset=7/1815; DF=1,726, *Z*=-1.2579, *P(Z)*=0.2084, Nonset=7/794; binomial GLM), while the GMHI showed no significant association with IBD onset. 338 339 340 341 342 343 344

IBD pathologies were consistently the most influential health conditions for the taxonomic and functional differences of the microbial communities (Figure 3J & Figure 4D, Table S21). The most pronounced differences were between the healthy controls and CD patients, followed by the differences between healthy controls and UC patients, while functional and taxonomic differences between UC- and CD patients persist (see Table S16, Table S21). Together with the presence of a stoma/artificial bowel outlet (colostomy, ileostomy, permanent/temporary stoma), other pathologies that influence the anatomic structure or gut transition time, such as obstipation, diarrhea, and intestinal stenosis strongly influence the taxonomic and functional composition of the microbial communities (Figure 3J). Thus, chronic and acute diseases, which influence passage time, have a significant impact on the taxonomic and functional composition of the intestinal microbiome. This pattern remained 345 346 347 348 349 350 351 352 353 354 355

consistent even after excluding potential confounding effects such as age, BMI, sex, and IBD pathology (see Table S21). 356 357

In addition to the impact of different pathologies, most importantly IBD, we observed a significant impact of various pharmaceutical treatments on microbial communities. Interestingly, antibiotic treatments between 6 weeks and one year prior had significant but not prominent effects as reported by [40]. However, the most influential were drugs that modify the fecal passage time (*e.g.* Loperamide*,* surfactants), further pronouncing the strong and consistent association of BSS with community composition. In particular, these pharmaceuticals remained influential after correcting for IBD condition, age, BMI, and sex (Figure 3J, Table S22) and associated with higher levels of BSS ($W=24756$, $P=3.3910\times10^{-9}$) Wilcoxon-test). 358 359 360 361 362 363 364 365 366

Investigating the impact of macro and micronutrient intake on the microbiota revealed a very interesting parallel distribution of F20:4 (Eicosatetraenoic acid/Arachidonic acid) and MD/GMHI indices with the microbial community composition (Figure 3J, Figure S13G-I), which was the only nutrient whose intake associated with an increasing dysbiosis signal in the microbial community, in direct correlation (Figures S14J; Table S23), and consistent in follow-up time points (see Figure 3J & S13G-I; Table S23). This eicosanoid precursor can be a potent, immunologically active molecule [41] and its uptake at baseline was weakly correlated to MD (ρ =0.0486, P =0.0772, Spearman correlation), BMI (ρ =0.1278, *P*=4.7168×10⁻⁶), ASCA IgG (ρ =0.0647, *P*=0.0881), and calprotectin (ρ =0.0514, *P*=0.0648). Increasingly dysbiotic communities were further correlated to increasing consumption of glycogen, various amino acids and general protein uptake (ZE), which can be interpreted as elevated uptake of animal products (Figures S14J), which paralleled the gradients of inflammatory markers (*e.g.* calprotectin; see Figures S13D-F & Figures S13G-I). In contrast, the increased uptake of various vitamins and trace minerals, as well as long-chain 367 368 369 370 371 372 373 374 375 376 377 378 379 380

carbohydrates (e.g. ZB-Fiber) significantly coincided with a less inflammatory/disturbed community structure (GMHI and MD) and were associated with reduced physiological signs of inflammation, potentially via SCFA production [42]. The functional community composition was only associated with vitamin B derivatives and trace mineral consumption (see Figure 4D & Figure S17G-I; Table S23). 381 382 383 384 385

Uncharacteristic community clusters (DMM) are associated with dysbiosis and clinical signs of inflammation 386 387

Unsupervised community clustering revealed three community clusters, which do not fully correspond to previous reports [43], but share common indicators reported in the literature (Figure 4A). Cluster-1 is characterized by a high abundance of *Prevotella* and *Ruminococcaceae* (*Prevotella*: P_{FDR} =1.1162×10⁻²⁶; *Ruminococcus*: P_{FDR} =2.1846×10⁻⁵⁹; Kruskal test), while cluster-2 shows a high abundance of *e.g. Bacteroides* and *Faecalibacterium* (*Bacteroides:* P_{FDR} =1.4604×10⁻¹⁷; *Faecalibacterium:* P_{FDR} =1.5310×10⁻⁸⁴; Kruskal test). In contrast, individuals in Cluster-3 showed a greater propensity for inflammation as indicated by the elevated MD-index $(P<2.2\times10^{-16})$; Kruskal test, Figure 4B & 4C) and community variability (Figure 4D), as well as increased levels of physiological inflammation markers such as ASCA-IgG/IgA, and increased stool moistness/softness (Figure S18A). This cluster further showed a higher abundance of *Enterobacteriaceae* (*e.g. Escherichia/Shigella:* P_{FDR} =4.0936×10⁻⁶¹; Kruskal test), which is unconventional for so-called "enterotypes". However, this community type has been reported before and appears to correspond to a dysbiotic community state, positioned outside the standard community states reported sofar [44–46]. In addition, we detected a significantly greater level of genetic risk for CD ($F_{2,1665}$ =12.5869, $P=3.7541\times10^{-6}$; LM) and general IBD ($F_{2,1665}$ =4.3156, $P=0.0135$; LM) among individuals in this unconventional community cluster, but not for UC risk 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404

 $(F_{2,1665}=0.1712, P=0.8427;$ Figure S18B), indicating the strong effect of IBD and a broad genetic disease risk on community composition. 405 406

Imputed community functions reveal the importance of amino acid related pathways and bacterial surface structures in health and disease 407 408

On average, communities differ more strongly between IBD pathologies based on the imputed functions compared to taxonomic differences, particularly regarding the difference between healthy controls and CD patients (Table S16). The ranking of single associations of pathologies, physiological parameters, and pharmaceutical treatments with functional community differences overlaps with the taxon-based analyses, although fewer associations can be detected (Figure 4E & 4F, Figure S17, Table S17, S21, S22, S23). Additionally, physiological signs of inflammation, such as ASCA IgA/IgG or decreasing stool consistency parallel the dysbiosis gradient in the functional composition (Figure 4E, Figure S17, Figure S17D; Table S16, S17). The MD-index and GMHI explained a greater percentage of community variation at the functional level (see Figure 4A, Figure S17M; Table S16), while functional community differences were only weakly correlated with the genetic risk scores for CD (*P*<0.05; Figure S6E). 409 410 411 412 413 414 415 416 417 418 419 420

At the level of single functions, we detected various differentially abundant KEGG Orthologous Groups (BL: $N_{total} = 5071$, F1: $N_{total} = 4347$; F2: $N_{total} = 4402$). By investigating systematic changes in functional abundances via Gene Set Enrichment Analysis [47], we identified various highly persistent functional differences between disease states, which were further supported in the external cohorts (Table S24). Various metabolic pathways involved in the metabolism and biosynthesis of amino acids, ranging from general *Biosynthesis of amino acids*, to *Phenylalanine, tyrosine and tryptophan biosynthesis,* among others, are consistently enriched in healthy individuals or rarely in UC patients compared to CD patients. Other amino acid-related pathways were similarly enriched in healthy individuals (*Arginine biosynthesis;* 421 422 423 424 425 426 427 428 429

Alanine, aspartate and glutamate metabolism; Valine, leucine and isoleucine biosynthesis; Lysine biosynthesis; see Figure 4E; Table S24). Basic metabolic functions and cell growth were more strongly represented in healthy controls and were repeated among the other cohorts in a similar direction (*e.g. Citrate cycle (TCA cycle), Oxidative phosphorylation*; Figure 4H, Figure S19-S22; Table S24), as were pathways involved in bacterial motility and biofilm formation, which were enriched in healthy individuals (*Bacterial chemotaxis, Flagellar assembly, Biofilm formation - Pseudomonas aeruginosa*). Oxidative phosphorylation also entails anaerobic electron transfer reactions (anaerobic respiration) that reduce other electron acceptors than oxygen for ATP generation (*e.g.* nitrate, sulfate, fumarate), as performed by various intestinal bacteria (*e.g. Desulfovibrio*). In contrast, functions related to carbohydrate degradation (*e.g. ABC transporters, Phosphotransferase system (PTS), Fructose and mannose metabolism, Galactose metabolism*) were very consistently enriched in IBD-associated communities and may, in combination with changing SCFA levels (F1 & F2: *Propanoate metabolism and Butanoate metabolism*), contribute to mucosal degradation. Bacterial traits that are central to the generation and integration of immune modulatory factors of gramnegative (*Lipopolysaccharide biosynthesis*) and gram-positive bacteria (*Teichoic acid biosynthesis, Peptidoglycan biosynthesis*) were also consistently enriched among IBD patients (Figure S19-S22; Table S24). 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447

Network analyses show systemic and transferrable patterns of community disturbance, and high disease dependent taxon centrality in community networks 448 449

To analyze the microbial community as a whole, we constructed co-abundance networks to identify important taxa and patterns in the fecal microbial communities that may be central for community and host homeostasis (Figure 5A). Across networks (split by time point, or by time point and pathology), we observed significant differences in the composition and topography at the network level between IBD pathologies and healthy community networks in 450 451 452 453 454

the KINDRED cohort (control *vs.* IBD: $F_{1,7}$ =2.4873, *P*=0.0947, R^2 =0.2622, *adj.* R^2 =0.1568; see Figure 5B),. This also held true when external IBD cohorts were included (Control *vs*. IBD: $F_{1,12}$ =2.1301, *P*=0.0604, R^2 =0.1507, *adj.* R^2 =0.0800, Control *vs*. IBD (incl. general IBD networks): *F*1,18=2.4144, *P*=0.0412, *R ²*=0.1183, *adj. R ²*=0.0693, Graphlet distance; Figure 5C & Figure S27A). Furthermore, we observed signs of network/community contraction in IBD communities in the KINDRED cohort, as implied by the increasing network density and radius in diseased community networks, which remained consistent when we included networks derived from healthy and diseased external cohorts (Figure S27B). In addition, "natural connectivity" is increased in IBD communities, which strongly suggests a greater resistance to disturbances or stochastic changes by those communities. A higher "natural connectivity" after disease manifestation implies more densely connected networks with fewer bottlenecks, and pronounced community structure, which tend to possess a greater robustness against random fluctuations and community decay [48,49]. 455 456 457 458 459 460 461 462 463 464 465 466 467

At the single taxon level/node level (Figure 5A, Figure S23-S26), we observed various pathogenic and IBD associated groups, consisting mainly of *Clostridium XVIII ramosum* (*Erysipelotrichaceae*: ASV_193) and *Clostridium XlVa clostridioforme/spec.* (e.g. ASV_103, ASV 171), as well as various members of the oral community (e.g. *Veillonella, Rothia, Cand. Saccharibacteria, Fusobacterium)* and *Enterobacteriaceae* (*e.g. Klebsiella*), to be consistently central across time points (particularly in diseased networks) and characteristically abundant in IBD patients. Similarly *Flavonifractor plautii* (ASV_93, *Ruminococcaceae*) or the Actinobacterium *Eggerthella lenta* (ASV 713), are elevated as well in IBD, highly central, and known for pro-inflammatory characteristics [50–54] (Figure S23-S26, Table S25). In contrast, ASVs belonging to *Alistipes* (*i.e. A. putredinis*, *Alistipes spec.*, *A. shahii*) are highly central and consistently abundant in control individuals across time points and external cohorts, like other SCFA producing bacteria (e.g. *Porphyromonadaceae: Barnesiella,* 468 469 470 471 472 473 474 475 476 477 478 479

Odoribacter, Parabacteroides spec.; *Lachnospiracea: Clostridium XlVb uncl*.; *Ruminococcacea* (*Clostridial cluster IV*, *Ruminococcus;* Figure 5A, Figure S23-S26, Table S25). However, through the nature of network construction through statistical means, centralities, and key-stone status may vary [55,56]. 480 481 482 483

Heritability of microbial taxa 484

Using a mixed model framework, we investigated the heritability of single ASVs using pedigree relationships in the cohort. Most of these associations were driven not only by host kinship or family conditions, but also by environmental/ anthropometric/ lifestyle characteristics (age, sex, BMI, and IBD status). At the ASV level, the taxa showing the highest heritability estimates were mainly members of the *Bacteroides*, while particularly *Bacteroides uniformis* (ASV-6, h^2_{null} =0.4723) and *Paraprevotella uncl.* (ASV 84, h^2_{full} =0.4783) had the highest heritability estimates (Table S26). Most taxa were impacted by environmental influences in addition to the apparent kinship effect/familiar transmission $(h²_{null} < h²_{full};$ Figure 5D, Figure S28A; Table S26). Interestingly, potential probiotic bacteria abundant in healthy individuals, or mutualistic taxa (not associated to IBD) displayed high heritability (*e.g. Parabacteroides uncl., Feacalibacteria uncl., A. muciniphila, B. thetaiotaomicron, Alistipes uncl.*). *Akkermansia muciniphila* displayed a lower impact of environmental/anthropogenic variables $(h_{null}^2 > h_{full}^2)$ on the inheritance patterns, and displayed a better fit solely by relatedness $(h²_{null}=0.2573$, Figure 5D, Figure S28A), similar to other highly heritable taxa, such as the ubiquitous human gut commensal *Bacteroides uniformis* [57] (Table S26). However, among the top 25% percent of the most heritable ASVs, we observed disease-associated taxa, mainly belonging to the Proteobacteria such as e.g. *Escherichia/Shigella* (ASV-5, ASV-10) or the typical oral *Dialister invisus* (ASV-17, Firmicutes), which were more abundant in IBD patients. The community wide dysbiosis indices (MD-index and GMHI), showed relatively strong heritability as well, which implies a 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504

genetic influence or intra-family transmission of dysbiosis. GMHI was within the boundaries of ASV based estimates in our cohort $(h²_{full}=0.1401)$, while the heritability of the MD-index was clearly lower (h^2_{full} =0.0813) and distinctly lower than estimates reported by Turpin *et al.* 2016 $(h^2=0.2728)$ for the MD-index or the heritability estimates for IBD itself (CD: 0.25-0.42, UC: 0.04-0.15) [58,59]. Overall, heritability of the communities appears to be disturbed in cases of IBD, as we observed a reduced correlation of community composition and genetic distance (kinship, IBS distance) in IBD cases compared to healthy individuals (Figure S28B), although overall correlations were still significant (kinship- $r=0.4406$, $m^212=0.8059$) *P*=0.0009, IBS- *r*=0.4272, m²12=0.8175, *P*=0.0009; Procrustes test). 505 506 507 508 509 510 511 512 513

514

DISCUSSION 515

In this cohort study we investigated the state and evolution of IBD by combining taxonomic and functional microbial data from several successive time points with extensive anthropometric, medical, nutritional, and social information. Genome-wide association studies focusing on IBD revealed various genetic risk loci for IBD, which may contribute to immune dysregulation, antimicrobial immune reactions, and changes in host-microbiome homeostasis [60,17]. Various studies have investigated the interplay between microbes, metabolites, and host characteristics. These analyses revealed distinct physiological and microbial manifestations of the different IBD pathologies, which are reflected in external disease cohorts. The unsupervised community clustering (DMM community cluster 3) and significant differences of IBD patients across cohorts, highlight the severity of community turnover during IBD [46] and a strong signal of dysbiosis which may even warrant one or multiple distinct community states. Similarly, the strong differentiation of IBD-specific networks from healthy ones points to large changes in community dynamics after disease manifestation. These changes potentially result in a resilient or resistant community state as 516 517 518 519 520 521 522 523 524 525 526 527 528 529

implied by the more connected, denser, and robust networks after IBD manifestation (radius, density, natural connectivity) even across cohorts [49]. The consistently observed increased community variability in diseased individuals is a probable result of community transitions. This phenomenon, the so called "Anna Karenina pattern", describes a pattern in which microbial communities of dysbiotic/diseased individuals are more different from each other than communities of healthy individuals are among each other. This phenomenon may be attributed to a loss of regulation or strongly individualized stochastic effects on community composition after IBD development [61] and has been detected in other IBD studies [25,62– 64]. In summary, different community characteristics, such as increasing interindividual variability, greater community density/connectivity, and large compositional changes after IBD manifestation, point toward large and to some extend universal community transformations in IBD development. 530 531 532 533 534 535 536 537 538 539 540 541

Physiological and genetic markers of inflammation are strongly disease specific, associated to the microbiome, and associate to disease onset 542 543

The two main IBD pathologies, CD and UC, are physiologically, anatomically, and microbiologically quite distinct. We identified disease specific patterns in several physiological markers of IBD. In particular, anti-fungal ASCA IgG and IgA have strong associations to CD and IBD in general. ASCA Ig levels were not reported to be associated to high risk genetic markers of CD (CARD15/NOD2), but that its effect sizes might be genetically determined [65] . Thus, ASCA levels themselves are not genetically determined, but rather their responsiveness, which reflects the strngth of inflammatory reactions to environmental antigens, potentially also of bacterial origin. In contrast we showed a significant association with polygenic risk scores for IBD, particularly CD, which was not yet shown before (Lee et al., 2021), and might originate from the wider array of cumulative 544 545 546 547 548 549 550 551 552 553

genetic risk factors known since the investigation by Halfvarson et al., 2005. This strong relationship of the PRS was not present for other physiological IBD biomarkers in this study. 554 555

Similar to ASCA Ig levels, anti-glycoprotein 2 antibodies (GP2) have been described as strong biomarkers for IBD [33,35], while fecal calprotectin represents a biomarker of general intestinal inflammation. All displayed strong disease specific differences and are strongly correlated with bacterial community characteristics such as composition, diversity, dysbiosis indeces, but far weaker associated to the genetic risk scores for IBD. Bacterial taxa that associated to ASCA levels overlap only in parts with a recent study in UC patients at the family level (*e.g. Ruminococcaceae*) [66]. 556 557 558 559 560 561 562

Decreased stool consistency, an indicator of reduced intestinal transit time, elevated fecal water content and eventually diarrhea, are hallmarks of IBD pathology. Although not associated with genetic risk for IBD, stool consistency decreases dramatically with increasing dysbiosis, diversity, and community composition. Recently Vandeputte et al. showed the effects of fecal passage time on community patterns in a Belgian cohort, surpassing dietary and disease related signals [67,68]. We found similar patterns, with increasing passage time (lower BSS) associated with increasing populations of Bacteroidetes and decreasing abundances of Firmicutes members. These patterns have mostly a similar orientation, but are significantly exaggerated in IBD patients, which implies a greater impact of bacteria on passage time/stool consistency or a greater impact of passage time on the bacterial community under intestinal inflammation. In line with the centrality of stool consistency and transit time for community composition, we observed a strong gradient of community composition and IBD associated dysbiosis with decreasing transit time. Similarly, among the most influential pharmaceutical treatments in the cohort are anti-diarrhea drugs, and the most influential medical conditions in addition to IBD are conditions affecting fecal flow (stoma, obstipation, diarrhea, stenoses, etc.). Changes in transit time can change the taxonomic and functional 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578

composition-, bidirectionally interact with the microbiota, and alter the metabolite composition by transitioning from saccharolytic to proteolytic metabolism [69,70]. 579 580

We determined a clear connection between the genetic risk of IBD development, particularly CD and general IBD, and the microbial community composition or level of dysbiosis. This finding emphasizes the potential connection between genetic risk factors such as *e.g. FUT2* or *NOD2* [60,71] and their combined influence on the microbial community, potentially leading to dysbiotic community dynamics in interaction with environmental factors. Polygenic risk scores integrate the abundance and penetrance of known risk variants for diseases such as IBD into a single genome-wide risk to develop the disease. Although PRS effectively capture established IBD variants, these scores may not account for yet unidentified genetic factors and were mainly derived from cohorts of predominantly European ancestry, thus missing out population specific variants [24]. However, in this cohort genetic risk for general IBD and CD showed stable and repeated connections to microbial- and physiological indicators of IBD and were derived and applied in a central European cohort. The relatively weak association of UC-PRS with microbial community characteristics, in contrast points to a reduced importance of the host-microbe interactions and/or lower density and penetrance of associated risk variants in UC [72]. In alignment with this, UC patients displayed comparatively weak and fewer associations with the microbiome, as seen before [64]. However, the associations that were detected are mostly consistent with other studies [66,73]. Naturally, PRS for IBDs are higher in IBD cases than in controls, however the clear and significantly elevated risk levels and the weak, albeit significant, increase in the probability of developing IBD with a higher PRS emphazises the potential of these scores to stratify individuals at risk and underscores the close interaction between genetic risk and potential environmental triggers such as the microbiome in IBD development [17]. *Barnesiella sp.,* a common mucosa-associated butyrate producer, showed a positive association with CD risk in healthy individuals but was 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603

negatively associated with CD risk in diseased individuals. A recent study revealed that this taxon is associated with a TLR4 modulating variant (*biliverdin reductase A, BLVRA*), which increases the risk for CD, but may dampen inflammation in a diseased state through SCFA production [74–76]. In contrast, we detected a reversal of this pattern in the commonly "probiotic" *Bacteroides fragillis* [77], which displayed a positive association with CD-PRS in IBD and CD patients. PRS also encompass important IBD-associated genes/risk variants for autophagy (e.g. *ATG16L1*, *NOD2*), which are unable to sense the anti-inflammatory signals of this taxon and may thus result in a proinflammatory cytokine bias through this taxon [78]. 604 605 606 607 608 609 610 611

Broad genetic patterns, as determined by kinship, influenced the taxonomic and functional composition of the bacterial communities [79]. Social distance as well as broad relatedness have been described in detail to allow for bacterial transfer [80,81] and the transfer of potential phenotypes. Thus, horizontal and vertical intrafamily transmission [80], may add to the continuation and transfer of inflammation and dysbiosis as experimentally trackable in mouse experiments [82,83]. Interestingly the ubiquitous human gut commensal *Bacteroides uniformis* [57] among other *Bacteroides* species shows a strong association with host genetic variation as has been described elsewhere for humans and mice [84,76]. Although mainly commensals, which are associated to long chain carbohydrate degradation, this capability of *Bacteroides* may also drive pathogenic patterns in susceptible environments/hosts, due to the weakening of the mucosal barrier [85,86]. Thus, the varying genetic background of the host and strain/species specifc functional variation may explain the varying association of Bacteroides species to IBD, particularly in light of their relatively stable host-genetic associations [76]. However, in contrast to our study, the heritability of Bacteroidetes in general and *Bacteroides* in particular were shown to be low in twin studies [79], but were on a similar level with recent studies which used more complex kinships [87]. Another mucolytic species, *Akkermansia muciniphila,* was highly heritable in other studies, as well [79,87], and 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628

has often been associated with weight loss and metabolic health. Here we showed a clear association with non-IBD individuals, even though its role in IBD can be ambiguous [88,89]. The majority of heritable taxa belong to Firmicutes (149 ASVs *vs.* 96 ASVs other); however, highly heritable *Christensenellaceae* were not detected, potentially due to their low abundance/prevalence in the cohort [81,79,90]. Overall, the potential inheritance patterns we detected strongly resemble patterns of shared communities in mother-offspring comparisons, thus potentially highlighting the dominant matrilineal influence of these analyses [80]], although cohabitation could not be completely disentangled from family membership due to data restrictions. In addition we detected a general correspondence between differences of community composition and genetic distance, highlighting a community wide influence of genetics and heritability. This pattern appears to be disturbed among IBD patients, potentially due to the overwhelming effect of disease and related factors on the microbial communities which masks the broad genetic effects we detected. 629 630 631 632 633 634 635 636 637 638 639 640 641

Oralization of the intestinal community and blooming of Enterobactericeae are common IBD characteristics across cohorts 642 643

A strong microbial pattern in IBD, particularly for CD, arises from the highly consistent association of oral bacteria with the disease. Various taxa across different phyla with a typical oral origin show clear associations with IBD (*Cand. Saccharibacteria, Rothia, Veillonella, Dialister, Fusobacteria, Klebsiella*) and highlighted a potential loss of colonization resistance of the community or detrimental physiological alterations. *Cand. Saccharibacteria* (formerly TM7) is a rarely described obligate bacterial epibiont involved in IBD-related microbial dysbiosis and oralization [37], but appeared very consistently in the investigated cohorts [64]. Additionally, *R. muciliginosa* is an oral taxon with a clear association with IBD, which interestingly closely associates with *Cand. Saccharibacteria* (Figure S29). It may thus represent a potential host for this taxon in the intestinal environment, as it until recently 644 645 646 647 648 649 650 651 652 653

belonged to the same family as its oral hosts (*Actinomycetaceae*) [91]. Alternatively, this group may represent an independent TM7 group adapted to the intestinal environment, as observed in the ruminant TM7-G3 cluster [92] with its own host species. *F. nucleatum* and its cell components have been proposed as causal triggers of inflammation in e.g. rheumatoid arthritis [93] or even IBD [94], and have been implicated in the development of colorectal cancer [95]. Recent studies also displayed several overlapping, mostly oral bacteria associated to UC, such as *Veillonella dispar*, *Megasphaera micronuciformis*, *Haemophilus parainfluenzae*, and other *Enterobacteriaceae* [96] and a reduction of these ectopically colonizing oral bacteria can promote remission in IBD patients [66]. Furthermore, oralization of the microbiome and oral health itself are strongly associated to IBD development, risk, and severity [97,98]. 654 655 656 657 658 659 660 661 662 663 664

However, the most consistent pattern of IBD association was observed for *Enterobacteriaceae,* such as potentially oral *Klebsiella sp.*, which are highly proinflammatory and often associated with UC and PSC, although we mainly detected stable associations with CD and IBD [97]. In addition, *Escherichia/Shigella* show clear and valid pathogenic or proinflammatory characteristics [38,99] and appear to characterize a distinct, potentially dysbiotic community type (DMM cluster-3), as previously proposed [44,45]. Various *Enterobacteriaceae*, are known to elicit strong immunological reactions and are associated with the development of IBD at various levels ranging from ecological (facilitation [100]) to metabolic [101] interactions that allow these taxa to benefit from inflammatory processes [102]. However, some members of the *Escherichia/Shigella* have been shown to be beneficial for the immunological development early in life [103] or carry beneficial characteristics [104]. Differentially abundant taxa, particularly oral taxa (*Fusobacterium, Dialister, Veillonella*) and the abundance patterns of *Enterobacteriaceae* correspond well with a recent 665 666 667 668 669 670 671 672 673 674 675 676 677

large meta-analysis of IBD studies, as do abundances of potentially beneficial taxa (*e.g. Faecalibacterium, Ruminococcaceae, Alistipes*) [105]. 678 679

Amino acid metabolism and flagellar functions associate strongly with healthy individuals 680

Interestingly, one of the most enriched functions differing between healthy and diseased individuals is *Aminobenzoate Metabolism*. Anthranilate or 2-Aminobenzoic acid is a key metabolite of bacterial aromatic compound degradation, a precursor of tryptophan biosynthesis, and a key metabolite to reduce or even prevent IBD pathogenesis [106,107]. Additionally, other functions involved in amino acid- and tryptophan metabolism, *e.g. Phenylalanine, tyrosine and tryptophan biosynthesis*, were also enriched. Thus, aromatic amino acid biosynthesis appears to have a strong, and health relevant effect, as the enrichment of amino acid metabolism is very prominent in control subjects. Interestingly, bacterial functions involved in *Flagellar assembly* show a strong and consistent association with healthy subjects as well (antagonistic to IBD) and may arise from the abundance of so-called "silent" flagellins present in *Lachnospiraceae,* which have potential anti-inflammatory activity via TLR5 binding [108]. However, *Lachnospiraceae* derived flagellins display a strong immune reactivity in CD patients [109,110], which may represent an aberrant response driven by an already disturbed mucosal barrier, rather than a *de novo* reaction to members of the Lachnospiraceae [111,109] . *Clostridium clostridioforme* (*Clostridium XlVa*) is highly CD-specific and immunologically reactive according to our results and other studies [112,113]. A recent study identified a strong and cross cohort IBD association of *C. clostridioforme* with specific biosynthetic gene clusters, whose products lead to increased inflammation and mucosal barrier dysfunction [114]. *C. clostridioforme* strongly correlates with the concentration of the potentially pro-inflammatory long chained fatty acid eicosatetraenoic acid/arachidonic acid (F20:4) [113], and its uptake is positively associated to dysbiosis (*e.g.* long saturated: long unsaturated: lipoids) correlated with community 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702

composition and dysbiosis. Furthermore eicosatetraenoic acid positively associated with CDand UC-associated taxa, *R. gnavus* but also *C. clostridioforme*, whereas typical probiotic taxa showed a significant negative relationship with this metabolite [113]. In addition to its immune- and inflammatory characteristics, this fatty acid possesses bactericidal activity and the potential to disrupt bacterial cell membranes [115]. This might indicate that IBDassociated taxa might be able to metabolize and synthesize F20:4 and are less susceptible to it, while it interferes with the growth health-associated species [113,114]. In contrast, the consumption of vitamins, long-chain carbohydrates, and long unsaturated fatty acids is correlated with lower levels of dysbiosis [42,116]. Bacterial traits that are central to the generation and integration of immune modulatory factors of gram-negative (*Lipopolysaccharide biosynthesis*) and gram-positive bacteria (*Teichoic acid biosynthesis, Peptidoglycan biosynthesis*) on the bacterial surface are also consistently enriched among IBD patients. Comparable patterns of these surface/capsular and membrane factors have also been observed in a recent meta-analysis of various IBD cohorts [117]. 703 704 705 706 707 708 709 710 711 712 713 714 715 716

717

CONCLUSION 718

The KINDRED cohort is a prospective cohort study that collects biomaterial and various types of data from IBD patients and their first- or second-degree relatives. The main aim of the KINDRED cohort is to identify lifestyle factors as well as serum and stool markers associated with the onset of the disease (in initially healthy relatives with a positive family history for IBD) and to investigate the individual disease course in patients on a multiomic level, integrating lifestyle, genetics, and microbial information. Using this multiomic dataset we identified strong and generalizable dysbiosis gradients, which correspond strongly with IBD pathologies, physiological manifestations of inflammation (*e.g.* BSS, calprotectin, anti-GP2 and ASCA IgA/IgG), genetic risk for IBD and general risk of disease onset. Patterns of 719 720 721 722 723 724 725 726 727

overabundance and importance of various opportunistic pathogens (*e.g., Enterobacteriaceae, C. XIVa clostridioforme*), in addition to consistent patterns of oralization, characterize IBD patients. Functionally, pathways involved in amino acid metabolism and flagellar assembly are beneficial, while mucolytic functions are associated with IBD. Broad scale ecological patterns point totipping-point dynamics being involved in the drastic state transitions of communities into the chaotic communities characteristic for IBD (community variability, community differentiation). However, some limitations are present in this study. Healthy relatives were not examined in an examination center and all information about these individuals were obtained through self-administered questionnaires. Another potential weakness of the KINDRED cohort is its open design, where recruitment has run over a long period of time (from 2013, and ongoing), with a slow increase of onset cases, and steady decrease of participants with time due to lack of compliance or withdrawal from the study during the regular, yet only biennial follow-ups. 728 729 730 731 732 733 734 735 736 737 738 739 740

741

MATERIALS AND METHODS 742

Basic study design and cohort: The KINDRED cohort is a German-wide, prospective cohort study that collected both, questionnaire data and biomaterials from IBD patients and their (affected and unaffected) family members. Despite great efforts to include as many family members as possible, a focus has always been on unaffected individuals with a family history of IBD. The recruitment of study participants started in October 2013 and is still ongoing. Follow-up information and new biomaterial samples were collected prospectively at intervals of approximately two years (Figure S1-S3). As of April 2021, the IBD Family Cohort has thus enrolled 1497 IBD patients together with 1813 (initially) non-affected first- or seconddegree relatives from Germany (minimum age at inclusion: 7 years). Participants, including the IBD patients, were asked to provide questionnaire data and biomaterials (blood, stool, 743 744 745 746 747 748 749 750 751 752

hair) at baseline and after every 2 years of follow-up (Table S1 & S2). The resulting patient counts are shown in Table 1 and Figure 1A. In addition, physician-administered questionnaires were collected from IBD patients to obtain physician-validated information, such as diagnosis, disease pattern/location, activity, and medication (Table S1). Using these data, the Kiel IBD Family Cohort aims to facilitate the comprehensive molecular, clinical, lifestyle, nutritional, and sociodemographic characterization of patients and high-risk individuals, and to identify preclinical signs for the onset of IBD. Additional information on eligibility criteria, enrollment, data and biomaterial collection, as well as data management, and privacy protection is given in the Supplement of this article. A standard battery of questionnaires was used to assess self-reported dietary behavior (12 month recall questionnaire) and metrics of well-being and quality of life (quality of life index, Fatigue Severity Scale index), were also employed (see Supplement) [118–120]. Nutritional data were adjusted by total energy consumption to decouple caloric consumption from diet composition. Individuals with undefined or unclear IBD diagnosis but with intestinal inflammation (e.g. suspected CD/UC, colitis) are summarized under the category uIBD (undefined IBD, Table S3). 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768

Ethics and human samples: The KINDRED cohort study protocol was approved by the ethics committee of the Medical Faculty of Kiel University (AZ A117/13). Every study participant provided written informed consent on forms that were age-adapted. For participants under the age of 18 years, informed consent must also be signed by their parents. When the participants reached the ages of 12 and 18 years a new informed consent (reconsent) form was signed by the participants themselves and, in the case of 12-year-old adolescents, by their parents. 769 770 771 772 773 774 775

A cohort of treatment naïve and newly diagnosed IBD patients in an active disease state from Malta (naïve : N_{CD} =31, N_{UC} =25), including a healthy control cohort (N_{Cont} =96), was recruited 776 777

as described elsewhere [64]. In addition we included a Maltese patient cohort currently in disease remission and treatment (remission: $N_{CD} = 32$, $N_{UC} = 66$), as described recently [63]. 778 779

Individuals from the Swedish Inception Cohort in IBD (SIC IBD) were included as treatmentnaïve patients, between 20–77 years of age. Symptoms, such as diarrhea, abdominal pain, bloody or mucous stools for ≥ 2 weeks, were inclusion criteria. The final diagnosis of IBD was established according to internationally accepted criteria including clinical, microbiological, endoscopic, histological, and radiological evaluation $(N_{CD}=17, N_{UC}=16)$. Patients with gastrointestinal symptoms but without endoscopic and histological signs of IBD-associated inflammation were considered symptomatic controls (SC, N_{SC} =16). In addition, 17 healthy individuals were included as healthy controls $(N_{\text{cont}}=16)$, one failed sequencing). 780 781 782 783 784 785 786 787

Physiological measurements: Calprotectin (indicator of intestinal inflammation) was measured in fecal samples using a Bühlmann fCAL™ ELISA kit (BÜHLMANN LABORATORIES AG) and analyzed using SoftMax Pro Software (Molecular Devices). ASCA IgA/IgG and anti-GP2 IgA/IgG were measured externally using ELISA (Medipan GmbH) including batchwise calibration samples. Occult fecal blood was determined by PreventID® Haemo/HaptOccult (Preventis GmbH, Bensheim, Germany). Other immunological measures (CRP Hb) were obtained during the initial examination using standard clinical tests. 788 789 790 791 792 793 794 795

Polygenic Risk Scores: GSA data were quality controlled via gwas-qc (<https://github.com/ikmb/gwas-qc>) not correcting for closely related individuals in the cohort using hg19 (genome build 37) of the human genome and 1000 Genome reference set. Potential sample mix ups and unclear relatedness patterns were manually checked and corrected if needed. Imputation was performed after chromosome wise transformation into bgzip VCF files via plink2 [121]. Single VCF files were uploaded to hybridcomputing.ikmb.uni-kiel.de/webservice/sites/, imputed and phased via EagleImp 796 797 798 799 800 801 802

32

(Genome build: GRCh37/hg19, Reference: 1000 Genomes Phase 3, r² filter: 0.1, allowed reference swaps, and strand flips) [122]. 803 804

To examine the genetic susceptibility of individuals in the KINDRED cohort for IBD and its subtypes CD and UC we calculated Polygenic Risk Scores (PRS). GWAS summary statistics were taken from the meta-analysis of IBD from Liu et al [20]. The summary statistics are based on a total of 5956 CD and 6968 UC patients with an additional 21770 population of controls with European ancestry. PRS were calculated with *LDpred2* within the *bigsnpr* (v. 1.12.2) R package [123,36]. After quality control of the summary statistics [124] the method calculates a posterior mean effect size based on linkage disequilibrium information and base effect size for all remaining available markers in both data sets. We used the *auto*-method of *LDpred2*, which automatically estimated the parameter sparsity *p* and the SNP heritability h^2 and did not require to tune hyper-parameters in the validation set. 805 806 807 808 809 810 811 812 813 814

Stool sample processing: DNA extraction, sequencing and bioinformatics processing of 16S rRNA gene libraries from stool samples were performed as described previously in detail [125]. 815 816 817

Data processing: Data processing of 16S sequences was performed using DADA2 1.10 [126] via the workflow for big datasets [\(https://benjjneb.github.io/dada2/bigdata.html,](https://benjjneb.github.io/dada2/bigdata.html) https://github.com/mruehlemann/ikmb_amplicon_processing/blob/master/ 818 819 820

dada2_16S_workow_with_AR.R) resulting in abundance tables of Amplicon Sequence Variants (ASVs). All sequencing runs were handled separately for error correction, read merging, and combined chimera detection. ASVs underwent taxonomic annotation using the naïve Bayesian classifier implemented in DADA2 using the Ribosomal Database Project 16 release [127,128]. ASV sequences were aligned via NAST-alignment to the SILVA core database and filtered for informative sites (constant gaps, constant bases) in mothur [129]. Phylogenetic tree construction on ASV alignment generated was carried out using FastTree 821 822 823 824 825 826 827

2.1 with the CAT substitution model with Γ -correction and improved accuracy, employing more minimum evolution rounds for initial tree search [-spr 4], more exhaustive tree search [mlacc 2], and a slower initial tree search [-slownni] [130]. Unstratified KO categories of metagenome predictions were generated using the native ASV abundances and sequences in PICRUSt 2.5.0 using default workflows [131]. 828 829 830 831 832

Statistical methods: 833

Alpha diversity: Species richness (Chao1), Simpson diversity (1-D), and phylogenetic alpha diversity (Nearest Taxon Index [NTI], Net Relatedness Index [NRI]) were calculated and analyzed in R 3.5.3.17-19. Phylogenetic measures of alpha diversity [Nearest Taxon Index (NTI), and Net Relatedness Index (NRI)] were derived using the *PhyloMeasures* package, based on 999 permutations against a null model preserving relative species richness within the communities [132–134] [NRI=-1 × (MPDobserved-mean (MPDrandom))/SD(MPDrandom); $NTI=-1 \times (MNTDobserved-mean(MNTDrandom))/SD(MNTDrandom)$]. Both metrics are phylogenetic effect sizes, for which positive values indicate phylogenetic clustering, values close to zero indicate neutral or random community assembly, and negative values indicate phylogenetic overdispersion, either over the whole phylogenetic tree (NRI) or across the closest related species/tips of the phylogenetic tree (NTI). The relationships of physiologicaland microbial inflammation markers/indices with alpha diversity were analyzed using linear models after correcting for relevant covariates (LM: residuals(variable~gender+scaled BMI + scaled Age) \sim IBD (Contr., CD, UC, IBD) $*$ physiological variable). Model fits were visualized via *base* R and *jTools* [135]. General correlation of MD with alpha diversity was tested via simple linear models, segmented linear models (*segmented*), or polynomial linear models and assessed via the AIC. 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850

Beta diversity: Analyses were conducted via distance based (conditional) Redundancy analyses and permutative ANOVA, as well as with a multivariate test for homogeneity of 851 852

variances (10000 permutations) [136,137] using Bray-Curtis dissimilarity (differential abundance). Global and pairwise differences in community varaibility were assessed via permutation test of multivariate homogeneity of group dispersions (10'000 permutations, via the *betadisper* function). Community clustering according to anthropometric, community distances of naïve and rarefied communities were highly correlated and thus higher coverage naïve samples were used for analysis (Bray-Curtis: Mantel: $r=0.9588$, $P<0.001$: Procrustes: m 2 12=0.06012, r=0.9695, P<0.001; Jaccard: Mantel: r=0.9941, P<0.001; Procrustes: m²12=0.006143, r=0.9969, P<0.001). 853 854 855 856 857 858 859 860

DMM community clustering: Community clustering was performed via Dirichilet Multinomial Mixture modeling as implemented in the R packages microbiome (*microbiome_1.20.0*) [138] and DirichletMultinomial (*DirichletMultinomial_1.40.0*) [139] after centered log ratio transformation (CLR) implemented in *compositions* [140]. The optimal number of clusters was determined via Laplace goodness of fit optimization in a range of 1-15 clusters. 861 862 863 864 865 866

Differential abundance analysis: Taxon abundances were filtered by having normalized counts of at least 5 among 1% of samples (*DESeq2* median of ratios transformation). Negative binomial GLMs with Wald tests as implemented in *DESeq2* (including automated effect filtering) were employed to detect differentially abundant taxa for each time point separately as well as for all time points combined [141] . To reduce the effect of potential confounding effects we included subject age, BMI and sex as covariates and in addition the time point itself, for the combined dataset. P-values were adjusted via FDR and only comparisons excluding the small subset of uIBD patients were investigated further (Contr./CD, Contr./UC, CD/UC, Contr./all-IBD). 867 868 869 870 871 872 873 874 875

Abundance \sim sex+ BMI (centered-scaled) + age (centered-scaled) [+ time point (BL/F1/F2)] + IBD pathology (Control, CD, UC, uIBD) 876 877

Abundance~sex+ BMI (centered-scaled) + age (centered-scaled) [+ time point $(BL/F1/F2)$] + Health status (Control/[CD, UC, uIBD]) 878 879

Similar methods were applied to investigate the functional characteristics of the bacterial communities, as based on imputed bacterial functions and pathways via PICRUSt2 [131]. To generalize the single KO associations, we performed Gene Set Enrichment Analyses using a function wise score $(-log10(P_{\text{Wald-test}}) \times sign(log$ fold change)) by multiplying the natural logarithm of P-values multiplied by the sign of fold change via clusterProfiler (4.4.4) using the *gseKEGG* function [47,142]. 880 881 882 883 884 885

Taxon abundances were correlated with a reduced set of clinical variables (ASCA IgA, ASCA IgG, anti-GP2 IgA, anti-GP2 IgG, fecal calprotrectin, BSS) as well as polygenic risk scores for IBD in general and for CD or UC in particular. CLR transformed species abundances were correlated with core physiological measures via *ppcor* [143], combining the P-values of Spearman-, Kendall-, and Pearson correlations via Brown's method to detect and incorporate the most consistent associations across different association measures [144]. The resulting Pvalues were FDR corrected and Spearman *ρ* was used for visualization via *ComplexHeatmap* $(v2.14.0)$ [145]. 886 887 888 889 890 891 892 893

Dysbiosis score: Dysbiosis scores based on the distribution of bacterial community members were calculated following Gevers *et al.* (2014) (Microbial Dysbiosis index/MD-index) and the more generalized General Microbiome Health Index (GMHI) as developed by Gupta *et al*. (2020) [38,39]. For the MD-index we combined significant taxa abundant in either CD or UC patients (uIBD not included) as compared to healthy/non-IBD cohort members at the baseline time point of the KINDRED cohort [log1p(sums(abundance CD, abundance UC)) / log1p(sums(non-IBD))]. GMHI was trained on the relative abundances at the baseline time point (training: 90%, testing: 10%) of the KINDRED cohort using code adapted from the Dutch Microbiome Project 894 895 896 897 898 899 900 901 902
(["https://github.com/GRONINGEN-MICROBIOME-CENTRE/DMP/tree/main/gmhi](https://github.com/GRONINGEN-MICROBIOME-CENTRE/DMP/tree/main/gmhi)"). 903

Physiological and microbial inflammation markers/indices were analysed using linear models including relevant covariates (variable~gender+scaled BMI + scaled Age + IBD (Contr., CD, UC, IBD)), followed by stepwise model selection to minimize AIC without significant loss of fit. The correlation of the MD/GMHI with alpha diversity was assessed with linear and quadratic fits and the best fit was selected via minimal AIC for each time point. Model fits were visualized via *base* R and *jTools* [135]. 904 905 906 907 908 909

Heritability analyses: To estimate the heritability of single communities in a rather heterogeneous and patchy pedigree with many confounding variables we applied a recently published approach employing linear mixed models, as implemented in *lme4qtl* (*relatLmer*) [146]. Thus, we were able to incorporate fixed effects in our heritability estimates using a kinship matrix based on reported pedigree information (*kinship2*) (Sinnwell et al., 2014) and CLR transformed taxon abundances. Evaluating the models with and without covariates (AIC, based on ML fit) allows us to further evaluate whether taxon heritability/family association is influenced significantly by environmental factors or family relations alone. To assess patterns among close relatives we categorized relatedness patterns (related (>1st degree), first degree (sibling, parent)) for comparison, as well as calculated distances between healthy family members and diseased and eventually diseased individuals (onsets). Similar techniques were applied for the analyses of KO heritability, including subject age and sex as covariates. Gene Set Enrichment Analyses were performed on K-numbers using a function wise score based on full h^2 estimates via clusterProfiler (4.4.4) using the *gseKEGG* function [142]. Communitywide correspondence between taxonomic and functional community dissimilarity and relatedness (kinship matrix, plink2 based "Identity by State" distance derived from imputed SNP sets) was assessed via PROCRUSTES tests (5000 permutations). 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926

37

Network analyses: Networks were generated individually for healthy and IBD (UC, CD) cohort subsets, as well as for the complete time point subsets. The node-based values (degree, betweenness, PageRank-index, eigenvalue-centrality, k-nearest neighbor degree) were calculated in *igraph* 1.2.4.1 [147–149]. Network-wide measures include centrality based assortativity [150], network diameter, radius, and size, density/clustering [151,152], and natural connectivity [48]. To assess whether bacteria were more important than expected by chance, observed centralities (mean of control subsamples) were compared against a permuted set of networks (10,000 times, combined for control subsamples) via one-sided Ztests. Graphlet (4-node) frequency correlation (*orca* v1.1-1, Spearman) based Euclidean distance [153,154] and an edge sharing distance (frequency of shared pairwise correlations) to assess network similarity between the different subgroup networks (CD, UC, Contr., IBD at baseline, follow-up 1, follow-up 2). 927 928 929 930 931 932 933 934 935 936 937 938

Onset association: To predict the binary outcomes of disease onset based on diversity measures and physiological/clinical variables, we employed generalized linear models with a binomial error structure and a "clog-log" link function ("complementary-log-log") as implemented in MASS [155]. The nonsymmetric complementary log-log link function ("cloglog") was chosen, for its ability to better cope with unbalanced distributions between positive and negative outcomes in the target variable [156]. Baseline samples with the addition of one follow-up 1 sample, which developed disease in the second follow-up, were used for prediction $(N_{onset}=7)$, in the context of all remaining baseline samples or only healthy baseline controls. Models included either no covariates, or the established set of covariates (scaled age, sex, scaled BMI). Model fits were visualized via *base* R and *jTools* [135]. 939 940 941 942 943 944 945 946 947 948

Models: 949

IBD-onset next time point $(1/0)$ ~ metric 950

IBD-onset next time point $(1/0)$ ~sex+ BMI (centered-scaled) + age (centered-scaled) + 951

metric/clinical variable 952

Data structure: BL (N_{onset} =4, N_{CD} =551, N_{UC} =438, N_{ulBD} =32, N_{contr} =787); BL-controls (N_{onset} =4, 953

 N_{contr} =787); BL+ (N_{onset} =7, N_{CD} =551, N_{UC} =438, N_{uIBD} =32, N_{contr} =787); BL-controls+ (N_{onset} =7, 954

 $N_{\text{contr}} = 787$ 955

956

ACKNOWLEDGEMENTS 957

We would like to thank Ilona Urbach, Ines Wulf, and Tonio Hauptmann of the IKMB microbiome laboratory and the staff of the IKMB sequencing facilities for their excellent technical support. This study was supported by the Deutsche Forschungsgemeinschaft (DFG) Research Unit 5042 ("miTarget-The Microbiome as a Therapeutic Target in Inflammatory Bowel Diseases"), the University of Malta, and the University of Örebro. Special thanks go to all participants of the KINDRED cohort study for enabling such a unique prospective study. 958 959 960 961 962 963

964

DECLARATIONS: 965

Funding: The KINDRED cohort received funding from the German Research Foundation (DFG) through Excellence Clusters "Inflammation at interfaces" (EXC 306) and "Precision Medicine in Inflammation" (PMI; EXC 2167), as well as from the Research Unit miTarget (FOR 5042). This study was also supported by a grant from the German Ministry of Education and Research (01ZX1606A). 966 967 968 969 970

Conflicts of interest: The authors declare that they have no conflicts of interest related to this article. 971 972

Availability of data and material: All KINDRED cohort data are stored and managed by the PopGen biobank at the Institute of Epidemiology at Kiel University, Germany. Researchers can apply for data access to the KINDRED data by submitting a research proposal, including the scientific background, research question, success prospects, study design, potential conclusions, and scientific collaborators of their study, at the local biobank P2N via the following form: http://www.uksh.de/p2n/Information+for+Researchers.html. Due to the informed consent obtained from the participants, phenotypes, as well as genotyping and all 16S rRNA gene-sequencing data, can not be deposited publicly. 973 974 975 976 977 978 979 980

Raw sequence data and relevant meta-data can be accessed online under the accession number PRJEB44440 (Malta IBD cases in remission), PRJEB47161 (Malta treatment naive IBD cases), PRJEB47162 (Malta controls) [63,64]; and data of the Swedish SIC-IBD inception cohort will be made available under the accession number PRJEB77933 at the European Nucleotide Archive (https://www.ebi.ac.uk/ena/) after acceptance of this manuscript at a peerreviewed journal. 981 982 983 984 985 986

Ethics approval: The study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of the Medical Faculty of Kiel University (AZ A117/13). Ethical approval for the Maltese cohorts was obtained from the University of Malta Research Ethics Committee (Ref 32/2017) and patients were recruited from the gastroenterology outpatient clinic at Mater Dei Hospital, Malta [63,64]. Ethical approval for the Swedish SIC-IBD cohort was obtained from the Uppsala Regional Ethics Committee (2010/313) and suspected IBD patients and controls were recruited from gastroenterological units at six Swedish hospitals. 987 988 989 990 991 992 993 994

Consent to participate: Informed consent was obtained from all individual participants included in the study (or, in the case of children, from their parents). Consent for publication: Not applicable. 995 996 997

40

Authors' contributions: GJ, SS, MK, CB, AF and WL designed the study; JE, GJ, and WL, LT and KJ conducted the study; LT, KJ and PRa curated the data; PE, RK, JJ and DR contributed external samples and additional clinical analyses; PRa and IR analyzed the data; PRa, IR, CB, WL and AF drafted the paper; all authors take responsibility for the final content. All authors have read the manuscript, made significant intellectual contributions and approved the final version of the manuscript. 998 999 1000 1001 1002 1003

1004

FIGURES 1005

Figure 1: (A) Individual transitions in the cohort between time points. The highlighted transitions are onset cases detected during the study's runtime ($N_{BL\rightarrow EI}$ =4, $N_{FL\rightarrow F2}$ =1, NF2→F3=2, , NF3→F4=3). **(B)** Analysis of selected physiological inflammation markers (ASCA IgA/IgG, Calprotectin, BSS) with respect to IBD condition and relevant covariates via linear models at baseline (see Table 1). Shown are only the optimal model results, after the model selection procedures are shown. Pairwise differences with respect to average differences, or differences in slope are highlighted in the plots $(\# P \le 0.1000, * P \le 0.0500, ** P \le 0.0100,$ *** *P*≤0.0010). **(C)** The violin plot displays the average differences of genetic predisposition to CD, UC and IBD in general, as based on *LDpred2* derived PRS. The average differences in PRS were tested via Wilcoxon rank tests contrasting healthy individuals, with healthy future onset cases (grey), CD patients (red), UC patients, and patients with undefined IBD (uIBD). In particular, compared with those in healthy controls, the average risk of IBD is significantly and consistently greater in patients with CD and UC, as well as in patients with future-onset disease. **(D)** Scatterplots show the significant relationships between polygenic risk scores for CD (PRS-CD) and selected physiological inflammation markers,between PRS-CD and ASCA IgG by considering anthropometric covariates (linear model on residuals) or without 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021

(Spearman correlation). Additional correlations of IBD- and UC-PRS with physiological markers can be found in Figure S4 and Table S5. 1022 1023

1024

Figure 2: Taxon differential abundances and predictability. **(A)** Overview of individual phylum abundances across time points and health conditions in the KINDRED Cohort. **(B)** Differential abundance analyses of ASVs based on the sample time point (BL). Displayed are the log fold changes for each ASV clustered by genus classification, including standard errors of the fold changes as indicated by individual error bars. Color indicates the phylum membership of the ASVs/Genera. DA only displays significant differential abundance for the respective comparison/contrast (*PFDR*≤0.05). **(C)** Partial correlation of CLR transformed taxon abundances with core physiological measures via *ppcor* [143], combining the *P* values of Spearman-, Kendall-, and Pearson correlations via Brown's method and corrected via FDR [144]. Correlations were adjusted for age, gender, and BMI and Spearman ρ is used to visualize correlation strength between taxa and clinical measures (# $P_{FDR} \le 0.1000$, * *PFDR*≤0.0500, ** *PFDR*≤0.0100, *** *PFDR*≤0.0010). Overlapping patterns of differential abundance for the respective taxa in the KINDRED cohort, Maltese- , and Swedish cohort is indicated in the bottom color bars. **(D)** Differences in species richness between healthy individuals, future onset cases, CD, UC, and uIBD cases (Wilcoxon test). Correlation of species richness with the microbial dysbiosis index (MD-index), which results in a negative, but non-linear relationship (optimal AIC based fit) between diversity and dysbiosis (BL (poly): $F_{2,1809}$ =226.97, $P \le 2.2 \times 10^{-16}$, *adj.R*²=0.1997; F1 (poly): $F_{2,645}$ =83.778, $P \le 2.2 \times 10^{-16}$, *adj.R*²=0.2037; F2 (poly): $F_{2,536}$ =55.745, *P*<2.2×10⁻¹⁶, *adj.R*²=0.1691; LM). Also the relationship between alpha diversity and several IBD relevant clinical measures, shows significant relationships between alpha diversity and host physiology, in a disease condition specific manner (see Table S15, Figure S11). Pairwise differences with respect to average 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046

differences, or differences in slope are highlighted in the plots (# *P*≤0.1000, * *P*≤0.0500, ** *P*≤0.0100, *** *P*≤0.0010). 1047 1048

1049

Figure 3: (A) Non-metric Multidimensional Scaling (NMDS) of Bray-Curtis distances among baseline samples, displaying the significant clustering by health conditions and significant correlations of clinical inflammation measures with community distance (BL, see Table S16 & Table S17). **(B)** NMDS displaying the gradient of community dysbiosis as expressed by MD-index [38], in parallel with clinical measures of inflammation and healthy onset cases highlighted in red (*, develop IBD in F1). **(C)** Correlation of MD-index and the first NMDS axis showing a clear gradient of dysbiosis in the community. Onset cases are distributed in the range of standard deviation around the mean of the community dsitribution (NMDS1) and the severity of dysbiosis (MD-index). **(D)** Community variability between health conditions as measured by the distance to the group centroid, is overall significantly different between health conditions ($F_{3,1808}$ =46.0315, P=0.00001, PERMANOVA), and significantly increased in CD and UC patients as compared to healthy controls (Table S19). **(E)** Principle coordinate analysis of German-, Swedish-, and Maltese samples, highlighting the transferrability of the dysbiosis gradient across cohorts (MD-index derived from german samples), **(F)** as well as a common disease wise clustering of communities irrespective of sample origin. **(G)** Community variability between health/IBD conditions within and between the German-, Swedish-, and Maltese cohorts showing a common theme of increased variability in IBD cases. **(H)** Mean differences of dysbiosis (MD-index derived from german samples) within and across cohorts, with the strongest differences between healthy and CD individuals. **(I)** Scatterplots visualize the correlation of selected physiological inflammation markers with the microbial dysbiosis score [38], and show disease specific differences as compared to healthy control individuals. Pairwise differences with respect to average differences, or differences in 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071

slope are highlighted in the plots (see Figure S16, Table S18; $#P \le 0.1000$, $* P \le 0.0500$, ** *P*≤0.0100, *** *P*≤0.0010). **(J)** Visualization of the explained variation of significant anthropometric variables as based on serial PERMANOVA of Bray-Curtis distances in all three time points available and focused on physiological measures (Table S17), different reported pathologies of individuals (Table S21), use of pharmaceuticals (Table S22), and nutrient intake as derived from FFQ data (Table S23). Variables are displayed if they show significant clustering in at least one time point $(\# P_{FDR} \le 0.1000, * P_{FDR} \le 0.0500,$ ** *PFDR*≤0.0100, *** *PFDR*≤0.0010). 1072 1073 1074 1075 1076 1077 1078 1079

1080

Figure 4: (A) Community clusters of the microbial community at the baseline time point, determined by Dirichilet Multinomial Mixture modelling (DMM) and optimal clustering was determined via Laplace goodness of fit optimization. **(B)** Overlay of the Microbial Dysbiosis score gradient (Gevers *et al.*, 2014) and community clusters (outlines), including healthy onset patients at baseline (indicated by *****). **(C)** Community clusters display a significantly elevated level of dysbiosis in clusters 2 and 3 (pairwise Wilcoxon tests), **(D)** as well as elevated levels of community variability in cluster-3 (PERMANOVA). **(E)** Non-metric Multidimensional Scaling (NMDS) of Bray-Curtis distances of PICRUSt2 based KO abundances among baseline samples (Douglas *et al.*, 2020), displaying the gradient of community dysbiosis as expressed by the taxonomy based MD-index (Gevers *et al.*, 2014), **(F)** and displaying the significant clustering by health conditions and significant correlations of clinical inflammation measures with community distance (see Table S16 & Table S17). Healthy IBD onset patients are highlighted in red (*, patients who developed IBD by the next follow-up). **(G)** Community variability between health conditions as measured by the distance to the group centroid, was significantly increased in CD and UC patients as compared to healthy controls (PERMANOVA, Table S19). **(H)** Density plots show the significant Gene 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096

Set Enrichments [142] of differentially abundant PICRUSt2 based KOs, between controls, CD patients, and UC patients (*P_{FDR}*≤0.05). Differential abundance was tested via *DESeq2* and the enrichment score was derived from the -log10(P-values)*direction of fold change (Table S23). Repeatedly detected metabolic pathways are highlighted in bold. 1097 1098 1099 1100

1101

Figure 5: (A) Spiec-Easi networks of baseline samples (N=1812). Bacterial nodes highlight significant differentially abundant ASVs in the network [157]. Bacteria not showing any differential abundance patterns between IBD patients and healthy controls are signified via (●), bacteria overabundant in IBD (combined CD, UC, uIBD) via (■) and bacteria more abudnant in controls are signified via (►). The barplot visualizes node centrality based on the number of connections (node degree) at the baseline time point. Colored boxes highlight corresponding ASV differential abundance patterns in KINDRED, external cohorts, and their association to IBD onset and remission. Significance of centralities is derived from Z-tests against a randomized networks (10'000). **(B)** Global network characteristics were derived from the baseline and disease specific sub-networks, which can be informative for stability and structure of the respective networks (Wilcoxon-test healthy vs. CD/UC). Network metrics include centrality based assortativity [150], network diameter, radius, and size as well as density/clustering [151,152], and natural connectivity [48]. **(C)** Network similarity of disease and time point specific sub networks, as well as subnetworks of external cohorts (Malta, Sweden) based on graphlet distance [153] and displayed via NMDS. Networks show a clear compositional difference between healthy and diseased networks (Control *vs.* IBD (incl. IBD networks): *F*1,18=2.4144, *P*=0.0412, *R ²*=0.1183, *adj. R ²*=0.0693; PERMANOVA). **(D)** Heritability estimates derived from the likelihood based method *lme4qtl* (Ziyatdinov *et al.*, 2018) using either only kinship information with or without additional environmental and anthropometric covariates (▲-incl. environmental covariates, ▼-no covariates). Only the 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121

- upper quartile of taxa are highlighted (based on h^2_{full} estimate including environmental 1122
- covariates). Additional information like differential abundance in IBD accross cohorts are 1123
- depicted for each taxon (Figure S28A, Table S26). 1124

1125

TABLES 1126

Table 1: Baseline characteristics of the IBD patients (N_{individuals}=1868) of the Kiel IBD Family Cohort. Values are mean ± standard deviation or absolute 1127

counts. Abbreviations: CD, Crohn's disease; IBD, inflammatory bowel disease; UC, Ulcerative colitis, uIBD, undefined inflammatory bowel disease. 1128

1129

1130

1131

Table 2: Analysis of major physiological characteristics across time points using linear models. Results depicted are models after variable selection 1132

minimizing AIC. 1133

1134 $\#$ centered and scaled

Table 3: Analysis of alpha diversity patterns across time points, correcting for age, sex, and 1135

BMI. 1136

1137

scaled and centered

1138

1139

1140

REFERENCES 1141

1. Burisch J, Jess T, Martinato M, Lakatos PL, on behalf of ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis [Internet]. 2013 [cited 2023 Mar 10];7:322–37. Available from: https://doi.org/10.1016/j.crohns.2013.01.010

2. Frolkis A, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak RN, et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol J Can Gastroenterol. 2013;27:e18-24.

3. Nunes T, Fiorino G, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: Is it genes or environment? World J Gastroenterol WJG [Internet]. 2011 [cited 2023 Mar 10];17:2715–22. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123468/

4. Zhao M, Burisch J. Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease. Dig Dis Sci. 2019;64:1759–69.

5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology [Internet]. 2012;142:46-54.e42; quiz e30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22001864

6. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol [Internet]. 2020 [cited 2023 Mar 10];5:17–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468125319303334

7. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet [Internet]. 2017 [cited 2023 Mar 10];390:2769–78. Available from:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)324480/fulltext

8. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.

9. Schreiber S, Rosenstiel P, Franke A. [Genetic etiology of chronic inflammatory bowel disease]. Internist. 2014;55:156–64.

10. Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map—Recent advances on the etiology of inflammatory bowel disease. Semin Immunol [Internet]. 2009 [cited 2023 Mar 10];21:334–45. Available from:

https://www.sciencedirect.com/science/article/pii/S1044532309000955

11. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol. 2015;110:564–71.

12. Capone K, Rosenberg HJ, Wroblewski K, Gokhale R, Kirschner BS. Change in Prevalence of Family History During Long-term Follow-up of Patients With Pediatric-onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2019;68:829–34.

13. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TIA, Binder V. Familial Occurrence of Inflammatory Bowel Disease. N Engl J Med. 1991;324:84–8.

14. Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31:14–23.

15. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet [Internet]. 2005;6:376–88. Available from: http://dx.doi.org/10.1038/nrg1607

16. Liu Z, Liu R, Gao H, Jung S, Gao X, Sun R, et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet [Internet]. 2023 [cited 2024 May 13];55:796–806. Available from:

https://www.nature.com/articles/s41588-023-01384-0

17. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.

18. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Metaanalysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–52.

19. Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. The Lancet [Internet]. 2016 [cited 2023 Mar 10];387:156–67. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00465-1/fulltext?rss %3Dyes=

20. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet [Internet]. 2015 [cited 2023 Mar 10];47:979–86. Available from: https://www.nature.com/articles/ng.3359

21. Ballester MP, Martí D, Tosca J, Bosca-Watts MM, Sanahuja A, Navarro P, et al. Disease severity and treatment requirements in familial inflammatory bowel disease. Int J Colorectal Dis. 2017;32:1197–205.

22. Borren NZ, Conway G, Garber JJ, Khalili H, Budree S, Mallick H, et al. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis. 2018;12:525–31.

23. Kevans D, Silverberg MS, Borowski K, Griffiths A, Xu W, Onay V, et al. IBD Genetic Risk Profile in Healthy First-Degree Relatives of Crohn's Disease Patients. J Crohns Colitis. 2016;10:209–15.

24. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet [Internet]. 2018 [cited 2024 Apr 11];19:581–90. Available from: https://www.nature.com/articles/s41576-018-0018-x

25. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature [Internet]. 2019;569:655–62. Available from: https://doi.org/10.1038/s41586-019-1237-9

26. Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, et al. The Integrative Human Microbiome Project. Nature [Internet]. 2019;569:641–8. Available from: https://doi.org/10.1038/s41586-019-1238-8

27. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, et al. Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. Cell Host Microbe [Internet]. 2015;18:489–500. Available from: file://www.sciencedirect.com/science/article/pii/S1931312815003777

28. Torres J, Burisch J, Riddle M, Dubinsky M, Colombel J-F. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut [Internet]. 2016 [cited 2024 Apr 19];65:1061–9. Available from: https://gut.bmj.com/content/65/7/1061

29. Argmann C, Hou R, Ungaro RC, Irizar H, Al-Taie Z, Huang R, et al. Biopsy and bloodbased molecular biomarker of inflammation in IBD. Gut [Internet]. 2022;0:1–17. Available from: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-326451

30. Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology [Internet]. 2020;159:96–104. Available from: https://doi.org/10.1053/j.gastro.2020.03.007

31. Leibovitzh H, Lee S-H, Garay JAR, Espin-Garcia O, Xue M, Neustaeter A, et al. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis. Gut [Internet]. 2023 [cited 2023 Aug 31];72:1462–71. Available from: https://gut.bmj.com/content/72/8/1462

32. Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J, et al. Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis. Gastroenterology. 2021;160:1532–45.

33. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut [Internet]. 2009 [cited 2024 Jun 6];58:1620–8. Available from: https://gut.bmj.com/content/58/12/1620

34. Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW. Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med. 2014;52:483–94.

35. Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66:137–44.

36. Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinforma Oxf Engl. 2021;36:5424–31.

37. Kuehbacher T, Rehman A, Lepage P, Hellmig S, Fölsch UR, Schreiber S, et al. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol. 2008;57:1569–76.

38. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15:382–92.

39. Gupta VK, Kim M, Bakshi U, Cunningham KY, Davis JM, Lazaridis KN, et al. A predictive index for health status using species-level gut microbiome profiling. Nat Commun [Internet]. 2020;11. Available from: http://dx.doi.org/10.1038/s41467-020-18476-8

40. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature [Internet]. 2018;555:623–8. Available from: http://dx.doi.org/10.1038/nature25979

41. Bennett M, Gilroy DW. Lipid Mediators in Inflammation. Microbiol Spectr [Internet]. 2016 [cited 2023 May 26];4:4.6.06. Available from:

https://journals.asm.org/doi/10.1128/microbiolspec.MCHD-0035-2016

42. Benus RFJ, Van Der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJM, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr [Internet]. 2010;104:693-700. Available from: http://dx.doi.org/10.1017/S0007114510001030

43. Vieira-Silva S, Sabino J, Valles-Colomer M, Falony G, Kathagen G, Caenepeel C, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstructionassociated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol [Internet]. 2019 [cited 2023 May 4];4:1826–31. Available from: https://www.nature.com/articles/s41564-019- 0483-9

44. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatol Baltim Md. 2013;57:601–9.

45. Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol [Internet]. 2017;3:8–16. Available from: https://doi.org/10.1038/s41564-017-0072-8

46. Frioux C, Ansorge R, Özkurt E, Ghassemi Nedjad C, Fritscher J, Quince C, et al. Enterosignatures define common bacterial guilds in the human gut microbiome. Cell Host Microbe [Internet]. 2023 [cited 2023 Jun 30]; Available from: https://www.sciencedirect.com/science/article/pii/S1931312823002172

47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

48. Jun W, Barahona M, Yue-Jin T, Hong-Zhong D. Natural Connectivity of Complex Networks. Chin Phys Lett [Internet]. 2010 [cited 2023 Aug 27];27:078902. Available from: https://dx.doi.org/10.1088/0256-307X/27/7/078902

49. Oehlers M, Fabian B. Graph Metrics for Network Robustness—A Survey. Mathematics [Internet]. 2021 [cited 2023 Jul 19];9:895. Available from: https://www.mdpi.com/2227- 7390/9/8/895

50. Robertson LW, Chandrasekaran A, Reuning RH, Hui J, Rawal BD. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol [Internet]. 1986 [cited 2023 May 13];51:1300–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC239061/

51. Salaritabar A, Darvishi B, Hadjiakhoondi F, Manayi A, Sureda A, Nabavi SF, et al. Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review. World J Gastroenterol [Internet]. 2017 [cited 2023 Oct 26];23:5097-114. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537178/

52. Gupta A, Dhakan DB, Maji A, Saxena R, P.K. VP, Mahajan S, et al. Association of Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India. mSystems. 2019;4:e00438-19.

53. Moll JM, Myers PN, Zhang C, Eriksen C, Wolf J, Appelberg KS, et al. Gut Microbiota Perturbation in IgA Deficiency Is Influenced by IgA-Autoantibody Status. Gastroenterology [Internet]. 2021 [cited 2024 Feb 20];160:2423-2434.e5. Available from: https://www.gastrojournal.org/article/S0016-5085(21)00458-3/fulltext

54. Alexander M, Ang QY, Nayak RR, Bustion AE, Sandy M, Zhang B, et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe. 2022;30:17-30.e9. 55. Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol [Internet]. 2018 [cited 2024 Apr 17];16:567–76. Available from: https://www.nature.com/articles/s41579-018-0024-1

56. Röttjers L, Faust K. Can we predict keystones? Nat Rev Microbiol. 2019;17:193.

57. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature [Internet]. 2010;464:59–65. Available from: http://dx.doi.org/10.1038/nature08821

58. Gordon H, Trier Moller F, Andersen V, Harbord M. Heritability in Inflammatory Bowel Disease: From the First Twin Study to Genome-Wide Association Studies. Inflamm Bowel Dis [Internet]. 2015 [cited 2023 May 3];21:1428–34. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450891/

59. Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI, et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet [Internet]. 2016;48:1413–7. Available from: http://dx.doi.org/10.1038/ng.3693

60. Rausch P, Rehman A, Künzel S, Häsler R, Ott SJ, Schreiber S, et al. Colonic mucosaassociated microbiota is influenced by an interaction of crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A [Internet]. 2011;108:19030–5. Available from: http://www.pnas.org/content/early/2011/11/08/1106408108.abstract

61. Zaneveld JR, McMinds R, Thurber RV. Stress and stability: Applying the Anna Karenina principle to animal microbiomes. Nat Microbiol [Internet]. 2017;2:17121. Available from: https://doi.org/10.1038/nmicrobiol.2017.121

62. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol [Internet]. 2017 [cited 2023 Jan 18];2. Available from: /pmc/articles/PMC5319707/

63. Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, et al. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission. Auchtung JM, editor. Microbiol Spectr [Internet]. 2022;10:e0061622. Available from: https://journals.asm.org/doi/10.1128/spectrum.00616-22

64. Rausch P, Ellul S, Pisani A, Bang C, Tabone T, Marantidis Cordina C, et al. Microbial Dynamics in Newly Diagnosed and Treatment Naïve IBD Patients in the Mediterranean. Inflamm Bowel Dis [Internet]. 2023 [cited 2023 Feb 7];1–15. Available from: https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izad004/7025776

65. Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut [Internet]. 2005 [cited 2022 Oct 6];54:1237–43. Available from: www.gutjnl.com

66. Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, et al. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host Microbe [Internet]. 2018;24:600-610.e4. Available from: https://www.sciencedirect.com/science/article/pii/S1931312818304931

67. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4.

68. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut [Internet]. 2016 [cited 2024 Jan 31];65:57–62. Available from: https://gut.bmj.com/content/65/1/57

69. Boekhorst J, Venlet N, Procházková N, Hansen ML, Lieberoth CB, Bahl MI, et al. Stool energy density is positively correlated to intestinal transit time and related to microbial enterotypes. Microbiome [Internet]. 2022 [cited 2024 Apr 15];10:1–10. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01418-5

70. Procházková N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM. Advancing human gut microbiota research by considering gut transit time. Gut [Internet]. 2023 [cited 2024 Apr 15];72:180–91. Available from: https://gut.bmj.com/content/72/1/180

71. Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, et al. Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Med Genet [Internet]. 2020 [cited 2023 May 14];21:1–8. Available from:

https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-020-01115-w

72. Ellinghaus D, Bethune J, Petersen B-S, Franke A. The genetics of Crohn's disease and ulcerative colitis – status quo and beyond. Scand J Gastroenterol [Internet]. 2015 [cited 2024 Apr 19];50:13–23. Available from: https://doi.org/10.3109/00365521.2014.990507

73. Schirmer M, Stražar M, Avila-Pacheco J, Rojas-Tapias DF, Brown EM, Temple E, et al. Linking microbial genes to plasma and stool metabolites uncovers host-microbial interactions underlying ulcerative colitis disease course. Cell Host Microbe [Internet]. 2024 [cited 2024 Feb 19];32:209-226.e7. Available from:

https://www.sciencedirect.com/science/article/pii/S1931312823005085

74. Wegiel B, Otterbein L. Go Green: The Anti-Inflammatory Effects of Biliverdin Reductase. Front Pharmacol [Internet]. 2012 [cited 2024 Apr 11];3. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2012.00047/full

75. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell [Internet]. 2016 [cited 2024 Feb 27];167:1125-1136.e8. Available from: https://www.cell.com/cell/abstract/S0092-8674(16)31403-9

76. Rühlemann MC, Hermes BM, Bang C, Doms S, Moitinho-Silva L, Thingholm LB, et al. Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat Genet [Internet]. 2021;53:147–55. Available from: https://doi.org/10.1038/s41588-020-00747-1

77. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature [Internet]. 2008 [cited 2024 Mar 14];453:620–5. Available from: https://www.nature.com/articles/nature07008

78. Chu H, Khosravi A, Kusumawardhani IP, Kwon AHK, Vasconcelos AC, Cunha LD, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116–20.

79. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, et al. Genetic Determinants of the Gut Microbiome in UK Twins. Cell Host Microbe [Internet]. 2016;19:731–43. Available from: http://dx.doi.org/10.1016/j.chom.2016.04.017

80. Valles-Colomer M, Blanco-Míguez A, Manghi P, Asnicar F, Dubois L, Golzato D, et al. The person-to-person transmission landscape of the gut and oral microbiomes. Nature [Internet]. 2023;614:125–35. Available from: https://doi.org/10.1038/s41586-022-05620-1

81. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell [Internet]. 2014;159:789–99. Available from: http://www.sciencedirect.com/science/article/pii/S0092867414012410

82. Schulfer AF, Battaglia T, Alvarez Y, Bijnens L, Ruiz VE, Ho M, et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol [Internet]. 2018;3:234–42. Available from: http://dx.doi.org/10.1038/s41564-017-0075-5

83. Parker A, Romano S, Ansorge R, Aboelnour A, Le Gall G, Savva GM, et al. Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain. Microbiome [Internet]. 2022 [cited 2023 Sep 21];10:1–25. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01243-w

84. Wang J, Kalyan S, Steck N, Turner LM, Harr B, Künzel S, et al. Analysis of intestinal microbiota in hybrid house mice reveals evolutionary divergence in a vertebrate hologenome. Nat Commun. 2015;6:6440.

85. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol [Internet]. 2012;10:323–35. Available from: http://dx.doi.org/10.1038/nrmicro2746

86. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell [Internet]. 2016 [cited 2024 Apr 8];167:1339-1353.e21. Available from: https://www.sciencedirect.com/science/article/pii/S0092867416314647

87. Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature [Internet]. 2022;604:732–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35418674

88. Rajilić-Stojanović M, Shanahan F, Guarner F, De Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19:481–8.

89. Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, et al. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J [Internet]. 2012;6:2091–106. Available from:

http://dx.doi.org/10.1038/ismej.2012.39

90. Waters JL, Ley RE. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. BMC Biol [Internet]. 2019 [cited 2024 Apr 16];17:83. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819567/

91. Utter DR, He X, Cavanaugh CM, McLean JS, Bor B. The saccharibacterium TM7x elicits differential responses across its host range. ISME J [Internet]. 2020 [cited 2024 Apr 17];14:3054–67. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784981/

92. McLean JS, Bor B, Kerns KA, Liu Q, To TT, Solden L, et al. Acquisition and Adaptation of Ultra-small Parasitic Reduced Genome Bacteria to Mammalian Hosts. Cell Rep [Internet]. 2020;32:107939. Available from: https://doi.org/10.1016/j.celrep.2020.107939

93. Hong M, Li Z, Liu H, Zheng S, Zhang F, Zhu J, et al. Fusobacterium nucleatum aggravates rheumatoid arthritis through FadA-containing outer membrane vesicles. Cell Host Microbe [Internet]. 2023 [cited 2023 May 12];31:798-810.e7. Available from: https://www.cell.com/cell-host-microbe/abstract/S1931-3128(23)00123-3

94. Engevik MA, Danhof HA, Ruan W, Engevik AC, Chang-Graham AL, Engevik KA, et al. Fusobacterium nucleatum Secretes Outer Membrane Vesicles and Promotes Intestinal Inflammation. mBio [Internet]. 2021 [cited 2023 May 12];12:e02706-20. Available from: https://journals.asm.org/doi/10.1128/mBio.02706-20
95. Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science [Internet]. 2017 [cited 2023 Dec 10];358:1443–8. Available from:

https://www.science.org/doi/10.1126/science.aal5240

96. Rühlemann MC, Heinsen FA, Zenouzi R, Lieb W, Franke A, Schramm C. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut. 2017;66:753–4.

97. Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017;358:359–65.

98. Madsen GR, Bertl K, Pandis N, Stavropoulos A, Burisch J. The Impact of Periodontitis on Inflammatory Bowel Disease Activity. Inflamm Bowel Dis. 2023;29:396–404.

99. Conte MP, Longhi C, Marazzato M, Conte AL, Aleandri M, Lepanto MS, et al. Adherentinvasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: Phenotypic and genetic pathogenic features. BMC Res Notes [Internet]. 2014;7:748. Available from: https://doi.org/10.1186/1756-0500-7-748

100. Stecher B, Chaffron S, Käppeli R, Hapfelmeier S, Freedrich S, Weber TC, et al. Like will to like: Abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog [Internet]. 2010;6:e1000711. Available from: http://dx.doi.org/10.1371%2Fjournal.ppat.1000711

101. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature [Internet]. 2010 [cited 2023 Dec 12];467:426–9. Available from: https://www.nature.com/articles/nature09415

102. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae. Cell Host Microbe [Internet]. 2007;2:119–29. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1931312807001576

103. Vatanen T, Kostic AD, D'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell [Internet]. 2016;165:842–53. Available from:

http://www.sciencedirect.com/science/article/pii/S0092867416303981

104. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis [Internet]. 2008 [cited 2024 Apr 19];14:1012–8. Available from: https://dx.doi.org/10.1002/ibd.20377

105. Ma S, Shungin D, Mallick H, Schirmer M, Nguyen LH, Kolde R, et al. Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin. Genome Biol [Internet]. 2022 [cited 2024 Jun 11];23:1–31. Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02753-4

106. Zelante T, Iannitti RG, Cunha C, DeLuca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity [Internet]. 2013;39:372–85. Available from: http://dx.doi.org/10.1016/j.immuni.2013.08.003

107. Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, et al. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology. 2017;153:1504-1516.e2.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.07.23.24310327;](https://doi.org/10.1101/2024.07.23.24310327) this version posted July 24, 2024. The copyright holder for this preprint
Which was not certified by peer review) is the author/funder, who has granted med

108. Clasen SJ, Bell MEW, Borbón A, Lee D-H, Henseler ZM, de la Cuesta-Zuluaga J, et al. Silent recognition of flagellins from human gut commensal bacteria by Toll-like receptor 5. Sci Immunol [Internet]. 2023 [cited 2023 Sep 22];8:eabq7001. Available from: https://www.science.org/doi/10.1126/sciimmunol.abq7001

109. Alexander KL, Zhao Q, Reif M, Rosenberg AF, Mannon PJ, Duck LW, et al. Human Microbiota Flagellins Drive Adaptive Immune Responses in Crohn's Disease. Gastroenterology [Internet]. 2021 [cited 2024 Apr 18];161:522-535.e6. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521006338

110. Lee S-H, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, et al. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology [Internet]. 2021 [cited 2024 Apr 18];161:1540–51. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521032431

111. Turpin W, Lee S-H, Raygoza Garay JA, Madsen KL, Meddings JB, Bedrani L, et al. Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease. Gastroenterology [Internet]. 2020 [cited 2023 Jun 14];159:2092-2100.e5. Available from: https://www.sciencedirect.com/science/article/pii/S0016508520350216

112. Finegold SM, Song Y, Liu C, Hecht DW, Summanen P, Könönen E, et al. Clostridium clostridioforme: a mixture of three clinically important species. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2005;24:319–24.

113. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293–305.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.07.23.24310327;](https://doi.org/10.1101/2024.07.23.24310327) this version posted July 24, 2024. The copyright holder for this preprint
Which was not certified by peer review) is the author/funder, who has granted med

114. Elmassry MM, Sugihara K, Chankhamjon P, Camacho FR, Wang S, Sugimoto Y, et al. A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules. bioRxiv [Internet]. 2024 [cited 2024 Apr 18];2024.02.07.579278. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871352/

115. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol. 2010;85:1629–42.

116. Pham VT, Fehlbaum S, Seifert N, Richard N, Bruins MJ, Sybesma W, et al. Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study. Gut Microbes. 2021;13:1–20.

117. Ning L, Zhou Y-L, Sun H, Zhang Y, Shen C, Wang Z, et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat Commun [Internet]. 2023 [cited 2024 Apr 16];14:7135. Available from: https://www.nature.com/articles/s41467-023-42788-0

118. Dehne LI, Klemm C, Henseler G, Hermann-Kunz E. The German Food Code and Nutrient Data Base (BLS II.2). Eur J Epidemiol. 1999;15:355–9.

119. Nöthlings U, Hoffmann K, Bergmann MM, Boeing H. Fitting portion sizes in a selfadministered food frequency questionnaire. J Nutr. 2007;137:2781–6.

120. Wang J, Thingholm LB, Skiecevičie J, Rausch P, Kummen M, Hov JR, et al. Genomewide association analysis identifies variation in Vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet [Internet]. 2016;48:1396–406. Available from: http://dx.doi.org/10.1038/ng.3695

121. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Secondgeneration PLINK: Rising to the challenge of larger and richer datasets. GigaScience [Internet]. 2015;4:7. Available from: http://www.gigasciencejournal.com/content/4/1/7

122. Wienbrandt L, Ellinghaus D. EagleImp: fast and accurate genome-wide phasing and imputation in a single tool. Bioinforma Oxf Engl. 2022;38:4999–5006.

123. Privé F, Aschard H, Ziyatdinov A, Blum MGB. Efficient analysis of large-scale genomewide data with two R packages: bigstatsr and bigsnpr. Bioinforma Oxf Engl. 2018;34:2781–7.

124. Privé F, Arbel J, Aschard H, Vilhjálmsson BJ. Identifying and correcting for misspecifications in GWAS summary statistics and polygenic scores. HGG Adv. 2022;3:100136.

125. Thingholm LB, Bang C, Rühlemann MC, Starke A, Sicks F, Kaspari V, et al. Ecology impacts the decrease of Spirochaetes and Prevotella in the fecal gut microbiota of urban humans. BMC Microbiol [Internet]. 2021:21:276. Available from: https://doi.org/10.1186/s12866-021-02337-5

126. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods [Internet]. 2016;13:581–3. Available from: http://dx.doi.org/10.1038/nmeth.3869

127. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol [Internet]. 2007;73:5261-7. Available from:

http://aem.asm.org/cgi/content/abstract/73/16/5261

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.07.23.24310327;](https://doi.org/10.1101/2024.07.23.24310327) this version posted July 24, 2024. The copyright holder for this preprint
Which was not certified by peer review) is the author/funder, who has granted med

128. Lan Y, Wang Q, Cole JR, Rosen GL. Using the RDP classifier to predict taxonomic novelty and reduce the search space for finding novel organisms. PLoS ONE [Internet]. 2012;7:e32491. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0032491

129. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol [Internet]. 2009;75:7537–41. Available from: http://aem.asm.org/cgi/content/abstract/AEM.01541-09v1

130. Price MN, Dehal PS, Arkin AP. FastTree 2 - Approximately maximum-likelihood trees for large alignments. PLoS ONE [Internet]. 2010;5:e9490. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0009490

131. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol [Internet]. 2020;38:685– 8. Available from: https://doi.org/10.1038/s41587-020-0548-6

132. Webb CO, Ackerly DD, McPeek MA, Donoghue MJ. Phylogenies and community ecology. Annu Rev Ecol Syst [Internet]. 2002;33:475–505. Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.ecolsys.33.010802.150448

133. Kembel SW, Cowan PD, Helmus MR, Cornwell WK, Morlon H, Ackerly DD, et al. Picante: R tools for integrating phylogenies and ecology. Bioinformatics [Internet]. 2010;26:1463–4. Available from:

http://bioinformatics.oxfordjournals.org/cgi/content/abstract/26/11/1463

134. Tsirogiannis C, Sandel B. PhyloMeasures: a package for computing phylogenetic biodiversity measures and their statistical moments. Ecography [Internet]. 2016;39:709–14. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ecog.01814

135. Long JA. jtools: Analysis and Presentation of Social Scientific Data [Internet]. 2022. Available from: https://cran.r-project.org/package=jtools

136. Legendre P, Andersson MJ. Distance-based redundancy analysis: Testing multispecies responses in multifactorial ecological experiments. Ecol Monogr. 1999;69:1–24.

137. Anderson MJ, Ellingsen KE, McArdle BH. Multivariate dispersion as a measure of beta diversity. Ecol Lett [Internet]. 2006;9:683–93. Available from: http://dx.doi.org/10.1111/j.1461-0248.2006.00926.x

138. Lahti L, Shetty S. Tools for microbiome analysis in R [Internet]. 2022. Available from: http://microbiome.github.io/microbiome

139. Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: Generative models for microbial metagenomics. PLoS ONE [Internet]. 2012;7:e30126. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0030126

140. van den Boogaart KG, Tolosana-Delgado R, Bren M. compositions: Compositional Data Analysis [Internet]. 2023. Available from: https://CRAN.R-project.org/package=compositions http://www.stat.boogaart.de/compositions/

141. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol [Internet]. 2014;15:550. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302049/

142. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS J Integr Biol [Internet]. 2012;16:284–7. Available from: https://www.liebertpub.com/doi/abs/10.1089/omi.2011.0118

143. Kim S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. Commun Stat Appl Methods [Internet]. 2015 [cited 2024 Feb 7];22:665–74. Available from: http://www.csam.or.kr/journal/view.html?doi=10.5351/CSAM.2015.22.6.665

144. Brown MB. 400: A Method for Combining Non-Independent, One-Sided Tests of Significance. Biometrics [Internet]. 1975 [cited 2024 Feb 7];31:987–92. Available from: https://www.jstor.org/stable/2529826

145. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics [Internet]. 2016 [cited 2024 Apr 3];32:2847– 9. Available from: https://doi.org/10.1093/bioinformatics/btw313

146. Ziyatdinov A, Vázquez-Santiago M, Brunel H, Martinez-Perez A, Aschard H, Soria JM. lme4qtl: linear mixed models with flexible covariance structure for genetic studies of related individuals. BMC Bioinformatics [Internet]. 2018 [cited 2023 Apr 3];19:1–5. Available from: https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-018-2057-x

147. Page L, Brin S. The anatomy of a large-scale hypertextual Web search engine. Comput Netw. 1998;30:107–17.

148. Freeman LC. Centrality in social networks conceptual clarification. Soc Netw. 1978;1:215–39.

149. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal Complex Syst. 2006;1695.

150. Newman MEJ. Assortative Mixing in Networks. Phys Rev Lett [Internet]. 2002;89:208701. Available from:

http://journals.aps.org/prl/abstract/10.1103/PhysRevLett.89.208701

151. Wasserman S, Faust K. Social Network Analysis: Methods and Applications. Cambridge University Press; 1994.

152. West DB. Introduction to Graph Theory. Prentice Hall; 2001.

153. Yaveroğlu ÖN, Malod-Dognin N, Davis D, Levnajic Z, Janjic V, Karapandza R, et al. Revealing the Hidden Language of Complex Networks. Sci Rep [Internet]. 2014 [cited 2024 Apr 9];4:4547. Available from: https://www.nature.com/articles/srep04547

154. Hočevar T, Demšar J. Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs. J Stat Softw [Internet]. 2016 [cited 2023 May 9];71:1–24. Available from: https://doi.org/10.18637/jss.v071.i10

155. Venables WN, Ripley BD. The S Language. Mod Appl Stat S [Internet]. New York, NY: Springer New York; 2002. p. 41–68. Available from: http://dx.doi.org/10.1007/978-0-387- 21706-2_3

156. Zuur AF, Ieno EN, Walker NJ, Saveliev AA, Smith GM. GLM and GAM for Absence– Presence and Proportional Data. Mix Eff Models Ext Ecol R [Internet]. New York, NY: Springer New York; 2009. p. 245–59. Available from: http://dx.doi.org/10.1007/978-0-387- 87458-6_10

157. Kurtz ZD, Müller CL, Miraldi ER, Littman DR, Blaser MJ, Bonneau RA. Sparse and Compositionally Robust Inference of Microbial Ecological Networks. PLoS Comput Biol [Internet]. 2015;11:e1004226. Available from:

http://dx.doi.org/10.1371%2Fjournal.pcbi.1004226

